<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html lang="en" xml:lang="en" xmlns="http://www.w3.org/1999/xhtml" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">


<meta name="wpd_version" content="0.2">
<meta name="wpd_baseurl" content="http://jac.oxfordjournals.org/content/57/4/619.full">
<meta name="wpd_url" content="http://jac.oxfordjournals.org/content/57/4/619.full">
<meta name="wpd_date" content="2013-04-27T15:45Z">
<script async="" src="cb=gapi.loaded_0"></script>
      
      <title>HIV entry inhibitors: mechanisms of action and resistance pathways </title>
      <meta name="googlebot" content="NOODP">
      <meta name="HW.ad-path" content="/cgi/content/full/57/4/619">
      <meta content="/jac/57/4/619.atom" name="HW.identifier">
      <meta name="DC.Format" content="text/html">
      <meta name="DC.Language" content="en">
      <meta content="HIV entry inhibitors: mechanisms of action and resistance pathways" name="DC.Title">
      <meta content="10.1093/jac/dkl027" name="DC.Identifier">
      <meta content="2006-04-01" name="DC.Date">
      <meta content="Oxford University Press" name="DC.Publisher">
      <meta content="Verónica Briz" name="DC.Contributor">
      <meta content="Eva Poveda" name="DC.Contributor">
      <meta content="Vincent Soriano" name="DC.Contributor">
      <meta content="Journal of Antimicrobial Chemotherapy" name="citation_journal_title">
      <meta content="J. Antimicrob. Chemother." name="citation_journal_abbrev">
      <meta content="0305-7453" name="citation_issn">
      <meta content="1460-2091" name="citation_issn">
      <meta name="citation_author" content="Verónica Briz">
      <meta name="citation_author" content="Eva Poveda">
      <meta name="citation_author" content="Vincent Soriano">
      <meta content="HIV entry inhibitors: mechanisms of action and resistance pathways" name="citation_title">
      <meta content="04/01/2006" name="citation_date">
      <meta content="57" name="citation_volume">
      <meta content="4" name="citation_issue">
      <meta content="619" name="citation_firstpage">
      <meta content="627" name="citation_lastpage">
      <meta content="57/4/619" name="citation_id">
      <meta content="jac;57/4/619" name="citation_mjid">
      <meta content="10.1093/jac/dkl027" name="citation_doi">
      <meta content="http://jac.oxfordjournals.org/content/57/4/619.abstract" name="citation_abstract_html_url">
      <meta content="http://jac.oxfordjournals.org/content/57/4/619.full" name="citation_fulltext_html_url">
      <meta content="http://jac.oxfordjournals.org/content/57/4/619.full.pdf" name="citation_pdf_url">
      <meta content="http://jac.oxfordjournals.org/content/57/4/619" name="citation_public_url">
      <meta content="16464888" name="citation_pmid">
      <meta name="citation_section" content="Review">
      <meta name="robots" content="noarchive,nofollow">
      <meta name="googlebot" content="noarchive">
      <link href="http://jac.oxfordjournals.org/content/57/4/609.short" rel="prev">
      <link href="http://jac.oxfordjournals.org/content/57/4/628.short" rel="next">
      
      
      
      
      
      
      
      
      <script type="text/javascript" id="session-d250751244e1">var callbackToken='5498847E8B66D79';</script><script type="text/javascript" src="jquery-min.js"></script><script type="text/javascript" src="hw-shared.js"></script><script type="text/javascript" src="hw-publisher-site.js"></script><script type="text/javascript" src="local-js-vars.js"></script><script type="text/javascript" src="hw-content.js"></script><script type="text/javascript" src="AccessCheckLib.js"></script><script type="text/javascript" src="executeAccessCheck.js"></script><script type="text/javascript" src="jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="jquery.easing-1.3.pack.js"></script><script type="text/javascript" src="jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="content.jquery.addVariantLink.js"></script><script type="text/javascript" src="hw-col-expand.js"></script><script type="text/javascript" src="hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="hw-mathjax.js"></script><script type="text/x-mathjax-config;executed=true">

          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
       </script><script type="text/javascript" src="MathJax.js"></script>
      
      
      
      
      <script type="text/javascript" src="main.js"></script>
      <script type="text/javascript" src="oup_ad_size.js"></script><script src="common"></script><script src="policy"></script><script src="custom-script.js"></script><script src="oxford-www"></script>
<link rel="stylesheet" type="text/css" href="619.css" media="all">
</head>
<body class="general_page journal jac tex2jax_ignore"><div id="dic_bubble" class="selection_bubble fontSize13 noSelect" style="z-index: 9999; border: 1px solid rgb(74, 174, 222); visibility: hidden;"></div><div><div id="cookiepolicy_div"><a id="cookiepolicy_link" href="#cookiepolicy_data"></a><div id="cookiepolicy_parent" style="display: none;"><div id="cookiepolicy_data"></div></div></div></div><div style="display: none;" id="MathJax_Message"></div>
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content" itemscope="itemscope" itemtype="http://schema.org/ScholarlyArticle">
         <noscript>

            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="Journal of Antimicrobial Chemotherapy"><a href="http://jac.oxfordjournals.org/"><span>

                     Journal of Antimicrobial Chemotherapy
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jac/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="http://jac.oxfordjournals.org/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jac/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="http://jac.oxfordjournals.org/content/current"><span>View Current Issue (Volume 68 Issue 6 June 2013)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="http://jac.oxfordjournals.org/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="http://jac.oxfordjournals.org/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/" class="breadcrumb_subject">Medicine</a> <span class="ampersand"></span> </span></li>
            <li><a href="http://jac.oxfordjournals.org/">Journal of Antimicrobial Chemotherapy</a></li>
            <li><a href="http://jac.oxfordjournals.org/content/57/4.toc">
                  <span xmlns="" class="volume-value">Volume 57<span class="vol-issue-comma">,</span></span>
                  <span xmlns="" class="issue-value"> Issue 4</span></a></li>
            <li>Pp. <span class="slug-pages">

                  619-627.
                  </span></li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top" src="619_1.html" class="resize_ad yhkfnaqsgqmkflxzouey" frameborder="0" height="0" scrolling="no" width="0"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div class="10.1093jacdkl02710.1093jacdkl027" style="height: 19359px;" id="content-block"><div class="option-box-docked" style="display: block; left: 665.5px;" id="content-option-box" title="Expand this column"><ul><li id="content-toggle"><a href="#"><span class="descr">Expand</span><span>+</span></a></li></ul></div><div id="print-slug" class="print-only"><span class="jnl-title">Journal of Antimicrobial Chemotherapy</span><span class="jnl-url">jac.oxfordjournals.org</span><div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="Journal of Antimicrobial Chemotherapy" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">J. Antimicrob. Chemother.</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">

                                    (April 2006) 
                                    </span>
                                 
                                 <span class="slug-vol">

                                    57
                                    </span><span class="slug-issue">

                                    (4):
                                    </span><span class="slug-pages">

                                    619-627.
                                    </span>
                                 <span class="slug-doi-wrapper">

                                    
                                    doi:
                                    
                                    <span title="10.1093/jac/dkl027" class="slug-doi">10.1093/jac/dkl027</span>
                                    </span>
                                 </cite>
                              
                              
                              <span class="slug-metadata-note ahead-of-print">

                                 
                                 First published online:
                                 
                                 <span class="slug-ahead-of-print-date">February 7, 2006</span>
                                 </span>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div></div>
            <div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">HIV entry inhibitors: mechanisms of action and resistance pathways</h1>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder">&nbsp;</div><a href="#sec-1" title="Introduction" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  
                  <p id="p-1">Entry inhibitors represent a new generation of antivirals for the treatment of HIV infection. Several compounds which block
                     the attachment of HIV gp120 to either the CD4 T cell receptor or the CCR5/CXCR4 co-receptors are currently in clinical development.
                     Most of these compounds have different molecular structures and specific mechanisms of action. These agents are eagerly awaited
                     by a growing number of patients carrying viruses resistant viruses to many of the current available reverse transcriptase
                     and protease inhibitors. For enfuvirtide, the first and, so far, only entry inhibitor approved for clinical use, the main
                     mechanism of resistance is the selection of changes within a 10 amino acid segment encompassing residues 36–45 within the
                     HR1 region of gp41. For other entry inhibitors, multiple changes in different gp120 domains (V1, V2, V3, C2 and C4) have been
                     associated with loss of susceptibility to these agents, although in most cases with limited cross-resistance.
                  </p>
                  
               </div>
               <h3 class="kwd-header">Key words</h3>
               <ul class="kwd-group KWD">
                  <li class="kwd"><span><a class="kwd-search" href="http://jac.oxfordjournals.org/search?fulltext=antivirals&amp;sortspec=date&amp;submit=Submit&amp;andorexactfulltext=phrase">antivirals</a></span></li>
                  <li class="kwd"><span><a class="kwd-search" href="http://jac.oxfordjournals.org/search?fulltext=gp120&amp;sortspec=date&amp;submit=Submit&amp;andorexactfulltext=phrase">gp120</a></span></li>
                  <li class="kwd"><span><a class="kwd-search" href="http://jac.oxfordjournals.org/search?fulltext=CCR5&amp;sortspec=date&amp;submit=Submit&amp;andorexactfulltext=phrase">CCR5</a></span></li>
                  <li class="kwd"><span><a class="kwd-search" href="http://jac.oxfordjournals.org/search?fulltext=CXCR4&amp;sortspec=date&amp;submit=Submit&amp;andorexactfulltext=phrase">CXCR4</a></span></li>
               </ul>
               <div class="section" id="sec-1">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-2" title="CD4–gp120 binding" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Introduction</h2>
                  
                  <p id="p-2">Viral entry currently represents one of the most attractive targets in the search for new drugs to treat HIV infection. Thanks
                     to the advances in the knowledge of the molecular basis of the mechanisms involved in the entry process, it has been possible
                     to split it into several steps and design molecules to block each one of them. The main steps in the viral entry process are
                     (i) attachment of the viral gp120 to the CD4 T cell receptor, (ii) binding of the gp120 to CCR5 or CXCR4 co-receptors and
                     (iii) fusion of the viral and cellular membranes (<a id="xref-fig-1-1" class="xref-fig" href="#F1">Figure 1</a>). 
                     
                  </p>
                  <div id="F1" class="fig pos-float odd">
                     <div class="fig-inline"><a class="fig-inline-link" href="http://jac.oxfordjournals.org/content/57/4/619/F1.expansion.html"><img alt="Figure 1." src="F1.small.gif"></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a class="fig-inline-link" href="http://jac.oxfordjournals.org/content/57/4/619/F1.expansion.html">In this page</a></li>
                              <li><a target="_top" class="in-nw-vis" href="http://jac.oxfordjournals.org/content/57/4/619/F1.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="http://jac.oxfordjournals.org/powerpoint/57/4/619/F1">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label"><strong>Figure 1.</strong></span> 
                        <p id="p-3" class="first-child">HIV entry process. (a) CD4–gp120 binding, (b) gp120-co-receptor interaction and (c) viral and cellular membrane fusion.</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-4">Entry inhibitors are a new family of antiretrovirals presently represented only by one drug, enfuvirtide, the first fusion
                     inhibitor,<sup><a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a></sup> but many other compounds are in the process of clinical development and certainly will be part of the therapeutic armamentarium
                     within the next few months or years. These compounds are eagerly awaited and may prove beneficial for the growing number of
                     HIV-infected individuals who have developed resistance to the currently available reverse transcriptase (RT) and protease
                     inhibitors.
                  </p>
                  
                  <p id="p-5">The threat of resistance is always present in HIV therapeutics, and there is no doubt that HIV will develop resistance to
                     entry inhibitors also. However, the good news is that no cross-resistance with the currently available antiretrovirals is
                     expected given their distinct mechanisms of action. Herein, we review in detail how HIV entry inhibitors block each stage
                     of the entry process and which are the mechanisms by which resistance may develop (<a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table 1</a>). 
                     
                  </p>
                  <div class="table pos-float" id="T1">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="http://jac.oxfordjournals.org/content/57/4/619/T1.expansion.html">In this window</a></li>
                              <li><a target="_top" class="in-nw-vis" href="http://jac.oxfordjournals.org/content/57/4/619/T1.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label"><strong>Table 1.</strong></span> 
                        <p id="p-6" class="first-child">HIV entry inhibitors: mechanisms of action and resistance pathways</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
               </div>
               <div class="section" id="sec-2">
                  <div class="section-nav"><a href="#sec-1" title="Introduction" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-3" title="CD4–gp120 binding inhibitors and their mechanism of action" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>CD4–gp120 binding</h2>
                  
                  <p id="p-9">The identification in 1984 of the CD4 molecule as the major receptor used by HIV to enter into cells was a breakthrough in
                     the knowledge of HIV biology. The first step in the HIV entry process is initiated by the binding of HIV gp120 to CD4 on the
                     target cell surface.<sup><a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a>–<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a></sup> The viral protein gp120 is composed of an inner and an outer domain connected by a bridging sheet, a four-stranded antiparallel
                     β-sheet. In those domains are localized five conserved (C1–C5) and five variable (V1–V5) regions (<a id="xref-fig-2-1" class="xref-fig" href="#F2">Figures 2</a> and <a id="xref-fig-3-1" class="xref-fig" href="#F3">3</a>). The most critical regions involved in the viral entry process are V1/V2, V3 and C4. The three-dimensional functional structure
                     of gp120 has been characterized and shown to contain intramolecular disulphide bonds,<sup><a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a>,<a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a></sup> which are critical for the interaction with the CD4 receptor and any potential drug inhibitor. 
                     
                     
                     
                  </p>
                  <div id="F2" class="fig pos-float odd">
                     <div class="fig-inline"><a class="fig-inline-link" href="http://jac.oxfordjournals.org/content/57/4/619/F2.expansion.html"><img alt="Figure 2." src="F2.small.gif"></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a class="fig-inline-link" href="http://jac.oxfordjournals.org/content/57/4/619/F2.expansion.html">In this page</a></li>
                              <li><a target="_top" class="in-nw-vis" href="http://jac.oxfordjournals.org/content/57/4/619/F2.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="http://jac.oxfordjournals.org/powerpoint/57/4/619/F2">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label"><strong>Figure 2.</strong></span> 
                        <p id="p-10" class="first-child">Schematic representation of the HIV gp120 glycoprotein with five constant (C1–C5) and five variable (V1–V5) regions.</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <div id="F3" class="fig pos-float odd">
                     <div class="fig-inline inline-expansion"><a class="fig-inline-link" href="http://jac.oxfordjournals.org/content/57/4/619/F3.expansion.html"><img style="display: none;" class="previous-figure" alt="Figure 3." src="F3.small.gif"><img class="replaced-figure" src="F3.medium.gif" alt="Figure 3."></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li style="display: none;"><a class="fig-inline-link" href="http://jac.oxfordjournals.org/content/57/4/619/F3.expansion.html">In this page</a></li>
                              <li><a target="_top" class="in-nw-vis" href="http://jac.oxfordjournals.org/content/57/4/619/F3.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="http://jac.oxfordjournals.org/powerpoint/57/4/619/F3">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label"><strong>Figure 3.</strong></span> 
                        <p id="p-11" class="first-child">Three-dimensional view of HIV gp120.</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-12">The CD4 receptor binds between the outer and inner domains of HIV gp120. Its binding creates a cavity that is well-protected
                     and conserved among different HIV strains. Moreover, this cavity does not contain glycosylation sites.<sup><a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>,<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a></sup> These unique characteristics have encouraged its study as a therapeutic target in the search for new agents that may specifically
                     bind and block the initial step of HIV infection.
                  </p>
                  
                  <p id="p-13">Electrostatic forces mainly drive the CD4–gp120 binding, with the positive charge at the primary end of CD4 attracted to the
                     primary negative charge cavity of HIV gp120. Furthermore, van der Waals' forces and hydrogen bonds help to stabilize the CD4–gp120
                     interaction. The CD4 phenylalanine is the only residue that binds to this cavity; hence, the cavity of HIV gp120 has been
                     designated as the Phe-43 cavity. This residue is quite significant in CD4–gp120 binding because it is estimated that it alone
                     accounts for 23% of the total energy of CD4–gp120 binding.<sup><a id="xref-ref-7-2" class="xref-bibr" href="#ref-7">7</a>,<a id="xref-ref-8-2" class="xref-bibr" href="#ref-8">8</a></sup> Following the CD4–gp120 binding, the gp120 conserved core undergoes conformational changes, moving from the rigid to a flexible
                     state, allowing a subsequent interaction with the chemokine co-receptors.<sup><a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a></sup> The Phe-43 cavity in HIV gp120 was initially pursued as a potential target for small molecules that could bind it and block
                     the HIV entry.<sup><a id="xref-ref-8-3" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>,<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a></sup></p>
                  
               </div>
               <div class="section" id="sec-3">
                  <div class="section-nav"><a href="#sec-2" title="CD4–gp120 binding" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-4" title="Resistance to CD4–gp120 inhibitors" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>CD4–gp120 binding inhibitors and their mechanism of action</h2>
                  
                  <p id="p-14">There are many molecules able to inhibit gp120–CD4 binding, they have different structures and mechanisms of action. <strong>PRO-542</strong> (CD4–IgG2) is a tetravalent soluble recombinant antibody-like fusion protein that incorporates four copies of the virus-binding
                     CD4 domain<sup><a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a></sup> and mimics the CD4 receptor. It is one of the gp120–CD4 binding inhibitors in more advanced stages of clinical development.
                     Currently it is being evaluated in Phase II trials. Phase I studies concluded that PRO-542 was well tolerated without apparent
                     dose-limiting toxicities.<sup><a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a></sup> Moreover, pre-clinical studies combining PRO-542 and enfuvirtide have suggested synergy in the inhibition of HIV replication.<sup><a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a></sup> As a disadvantage, PRO-542 cannot be orally prescribed.
                  </p>
                  
                  <p id="p-15"><strong>TNX-355</strong> is a non-immunosuppressive monoclonal antibody directed against the CD4 receptor. It competes with HIV gp120 for CD4 binding.
                     Early <em>in vitro</em> studies reported that the antibody binding site in the CD4 receptor is different from the site involved in the interaction
                     with HIV gp120. Thus, TNX-355 might prevent post-viral binding conformational changes which are required for the successful
                     entry of HIV into the cell.<sup><a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a></sup> Preliminary trials in HIV-infected patients revealed that single doses of TNX-355 reduced plasma HIV-1 RNA load and increased
                     CD4+ T cells counts. A Phase II trial is in progress. The clinical application of TNX-355 may be constrained by the requirement
                     of infusion.<sup><a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16</a>,<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a></sup></p>
                  
                  <p id="p-16"><strong>CADA</strong> is a specific inhibitor of the CD4–gp120 binding that does not interact directly with the CD4 receptor or with gp120. CADA
                     antiviral activity is assumed to down-regulate the CD4 receptor expression at the post-translational level.<sup><a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>,<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a></sup></p>
                  
                  <p id="p-17"><strong>BMS-806</strong> binds with high affinity to HIV gp120, blocking the conformational changes induced in gp120 after CD4 binding.<sup><a id="xref-ref-7-3" class="xref-bibr" href="#ref-7">7</a>,<a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a>,<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a></sup> The binding of BMS-806 to HIV gp120 is specific, reversible and co-receptor independent.<sup><a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a>,<a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a></sup> The drug is inactive against HIV-2 and simian immunodeficiency virus (SIV). The molecule exhibits no significant cytotoxicity,
                     shows good oral bioavailability and lacks toxicity in animal models.<sup><a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a></sup> Furthermore, it shows microbicide activity in macaques.<sup><a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">25</a></sup></p>
                  
               </div>
               <div class="section" id="sec-4">
                  <div class="section-nav"><a href="#sec-3" title="CD4–gp120 binding inhibitors and their mechanism of action" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-5" title="gp120–co-receptor interaction" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Resistance to CD4–gp120 inhibitors</h2>
                  
                  <p id="p-18">Several <em>in vitro</em> models have tried to describe the mechanism of action of all these inhibitors, which still remains unclear. Because all these
                     molecules act in different ways, it is expected that their mechanisms of action will differ as well. As a consequence, resistance
                     may develop in any of the different pathways and no cross-resistance should be expected among these compounds.
                  </p>
                  
                  <p id="p-19"><em>In vitro</em> studies conducted with BMS-806 and related compounds (BMS-155) have shown that gp120 amino acids involved in resistance are
                     those surrounding the Phe-43 cavity and a water-filled channel that extends from this cavity to the inner domain. Several
                     changes in gp120 residues Trp-112, Thr-257, Ser-375, Phe-382, Met-426, Met-434 and Met-475 result in the escape of HIV strains
                     from BMS-806 and BMS-155 inhibitors.<sup><a id="xref-ref-7-4" class="xref-bibr" href="#ref-7">7</a>,<a id="xref-ref-20-2" class="xref-bibr" href="#ref-20">20</a>,<a id="xref-ref-21-2" class="xref-bibr" href="#ref-21">21</a></sup> It is interesting to note that the degree of sequence conservation in the nearby V1/V2 variable loops indirectly influences
                     the susceptibility to these drugs. Even though V1/V2 regions are not absolutely required for BMS-806 or BMS-155 binding to
                     gp120, its deletion may alter the susceptibility of some HIV strains to these inhibitors.<sup><a id="xref-ref-7-5" class="xref-bibr" href="#ref-7">7</a></sup> Thus, natural gp120 variability among different HIV-1 subtypes may account for differences in baseline susceptibility to
                     these compounds. Preliminary data suggest that BMS-806 activity might be compromised in some non-B subtypes, particularly
                     in subtypes C and CRF01_AE, which seem to be naturally resistant to BMS-806.<sup><a id="xref-ref-26-1" class="xref-bibr" href="#ref-26">26</a></sup></p>
                  
               </div>
               <div class="section" id="sec-5">
                  <div class="section-nav"><a href="#sec-4" title="Resistance to CD4–gp120 inhibitors" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-6" title="CCR5 antagonists and their mechanism of action" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>gp120–co-receptor interaction</h2>
                  
                  <p id="p-20">In addition to binding to the CD4 cell receptor, HIV needs to bind to a chemokine co-receptor to enter the cells. The main
                     co-receptors involved in HIV entry are by far CCR5 and CXCR4. The formation of the CD4–gp120 complex elicits conformational
                     changes in the viral envelope allowing it to interact with CCR5 or CXCR4.
                  </p>
                  
                  <p id="p-21">CCR5 and CXCR4 belong to the seven transmembrane G protein-coupled receptor family. They have an α-helix structure composed
                     of four transmembrane domains, three extracellular loops and one N-terminal domain. The CD4–gp120 complex binds to any co-receptor
                     through the V3 region although other HIV gp120 regions such as V1/V2 and C4 may also be involved in this interaction.<sup><a id="xref-ref-27-1" class="xref-bibr" href="#ref-27">27</a></sup> V3 amino acid sequences determine the use of CCR5 and/or CXCR4. Accordingly, HIV isolates may be classified as R5, X4 and
                     R5/X4 strains, depending on their co-receptor use.<sup><a id="xref-ref-28-1" class="xref-bibr" href="#ref-28">28</a></sup></p>
                  
                  <p id="p-22">The gp120–co-receptor binding mapping suggests that for R5 virus the N-terminal domain and the second extracellular loop (ECL2)
                     of HIV gp120 are essential for co-receptor recognition and therefore for the inhibitory activity,<sup><a id="xref-ref-29-1" class="xref-bibr" href="#ref-29">29</a>,<a id="xref-ref-30-1" class="xref-bibr" href="#ref-30">30</a></sup> whereas for X4 strains only ECL2 seems to be critical.<sup><a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a></sup></p>
                  
               </div>
               <div class="section" id="sec-6">
                  <div class="section-nav"><a href="#sec-5" title="gp120–co-receptor interaction" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-7" title="CXCR4 antagonists and their mechanism of action" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>CCR5 antagonists and their mechanism of action</h2>
                  
                  <p id="p-23">CCR5 and CXCR4 antagonists are divided into three groups depending on their size. Large molecules, such as PRO-140, or molecules
                     with a medium size, as Met-RANTES and AOP-RANTES, which are modified CCR5 natural ligands, make CCR5 inaccessible. Finally,
                     several small-molecule inhibitors directed against CCR5 (TAK-779, SCH-C, SCH-D, UK-427857 and GW-873140) or CXCR4 (AMD3100
                     and KRH-1636) have been developed.
                  </p>
                  
                  <p id="p-24">Most CCR5 antagonists are small molecules which block the gp120–CCR5 interaction after binding to the co-receptor. These molecules
                     mimic chemokines, which are the natural ligands of the co-receptor, inhibiting their effect. <strong>TAK-779</strong> was the first non-peptide molecule that blocked the <em>in vitro</em> replication of R5 strains by interfering in their interaction with the CCR5 co-receptor.<sup><a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32</a></sup> The binding site is localized in a CCR5 transmembrane cavity formed by the 1, 2, 3 and 7 co-receptor transmembrane regions.<sup><a id="xref-ref-33-1" class="xref-bibr" href="#ref-33">33</a></sup> TAK-779 has little oral bioavailability and its clinical development was discontinued due to local reactions at injection
                     sites which made its management difficult. However, further studies based on TAK-779 have led to the identification of TAK-220.
                     This compound blocks very effectively R5 strains replication and it is orally bioavailable.<sup><a id="xref-ref-34-1" class="xref-bibr" href="#ref-34">34</a></sup> Phase II clinical trials are currently ongoing.
                  </p>
                  
                  <p id="p-25"><strong>TAK-652</strong> is a new antagonist from Takeda Chemical Industries. It shows good oral bioavailability and <em>in vivo</em> studies have confirmed its high potency against HIV and a good safety profile.<sup><a id="xref-ref-35-1" class="xref-bibr" href="#ref-35">35</a></sup> Moreover, it shows broad antiviral activity against different HIV subtypes.
                  </p>
                  
                  <p id="p-26"><strong>PRO-140</strong> is a monoclonal antibody directed against the CCR5 co-receptor, and in this way it blocks the binding of HIV gp120. In addition
                     to the inhibiting the entrance of HIV-1 subtype B, PRO-140 is effective against A, C, E and F subtypes.<sup><a id="xref-ref-36-1" class="xref-bibr" href="#ref-36">36</a></sup> Phase I/II clinical trials are currently ongoing.
                  </p>
                  
                  <p id="p-27">The safety and tolerability of <strong>SCH-C</strong> (SCH-351,125) was recently evaluated.<sup><a id="xref-ref-37-1" class="xref-bibr" href="#ref-37">37</a></sup> SCH-C exerts potent <em>in vitro</em> antiviral activity against R5 strains. However, high doses of the drug have been associated with prolongations in the QT
                     cardiac interval. On the basis of this finding, the clinical development of SCH-C has been halted in favour of its analogues
                     <strong>vicriviroc</strong> (SCH-417, 690 or SCH-D)<sup><a id="xref-ref-38-1" class="xref-bibr" href="#ref-38">38</a></sup> and <strong>AD101</strong> (SCH-350,581). These CCR5 antagonists are orally bioavailable and interact directly with the CCR5 transmembrane cavity, inhibiting
                     HIV gp120 binding.<sup><a id="xref-ref-39-1" class="xref-bibr" href="#ref-39">39</a></sup> Even though a Phase II study with vicriviroc in treatment-naive HIV-infected patients was recently discontinued due to the
                     poor antiviral activity observed in some patients, the Phase II study in treatment-experienced patients is ongoing. Furthermore,
                     promising pharmacokinetic and pharmacodynamic properties of vicriviroc when boosted with 100 mg of ritonavir have awakened
                     much interest.<sup><a id="xref-ref-40-1" class="xref-bibr" href="#ref-40">40</a></sup></p>
                  
                  <p id="p-28"><strong>Maravirok</strong> (UK-427, 857) is an orally bioavailable CCR5 antagonist developed by Pfizer. Initial results from Phase II trials were very
                     promising. Almost all patients experienced a remarkable reduction in plasma viraemia (mean of 1.42 log) and remained suppressed
                     for at least 10 days post-treatment.<sup><a id="xref-ref-41-1" class="xref-bibr" href="#ref-41">41</a>–<a id="xref-ref-43-1" class="xref-bibr" href="#ref-43">43</a></sup> Maravirok binds to the transmembrane co-receptor cavity, within the 2, 3, 6 and 7 helix, which is different than the region
                     targeted by TAK-779.<sup><a id="xref-ref-44-1" class="xref-bibr" href="#ref-44">44</a></sup> The drug is currently in advanced steps of clinical development and is expected to be approved in the near future.
                  </p>
                  
                  <p id="p-29">Finally, <em>aplaviroc</em> (GW-873140) showed significant <em>in vitro</em> and <em>in vivo</em> antiviral activities, with mean declines in plasma viraemia of 2 logs.<sup><a id="xref-ref-45-1" class="xref-bibr" href="#ref-45">45</a>,<a id="xref-ref-46-1" class="xref-bibr" href="#ref-46">46</a></sup> However, in October 2005, GlaxoSmithKline announced the discontinuation of the clinical development of the drug due to the
                     appearance of unexpected serious hepatotoxicity. Studies performed with aplaviroc and other CCR5 antagonists (SCH-C and TAK-779)
                     showed that aplaviroc exerted potent activity against R5 viruses. The drug interacted directly with ECL2 and not with the
                     transmembrane cavity.<sup><a id="xref-ref-47-1" class="xref-bibr" href="#ref-47">47</a></sup> Due to this different mechanism of action, distinct resistance pathways could be expected and no cross-resistance with other
                     CCR5 antagonists, such as maravirok or vicriviroc, may be assumed.<sup><a id="xref-ref-48-1" class="xref-bibr" href="#ref-48">48</a></sup></p>
                  
                  <p id="p-30">The CCR5 co-receptor binding site in HIV gp120 is concealed by V1/V2 and V3. Once HIV gp120 binds to CD4 different conformational
                     changes occur and the CCR5 co-receptor binding site is exposed. In the absence of CCR5 antagonists, the CCR5 N-terminus interacts
                     with residues located in the bridging sheet and the V3 stem of HIV gp120, whereas ECL2 interacts with the V3 crown. In the
                     presence of an inhibitor, the conformation of ECL2 is modified and it can no longer interact with the V3 crown, therefore
                     inhibiting viral entry<sup><a id="xref-ref-39-2" class="xref-bibr" href="#ref-39">39</a></sup> (<a id="xref-fig-4-1" class="xref-fig" href="#F4">Figure 4</a>). 
                     
                     
                  </p>
                  <div id="F4" class="fig pos-float odd">
                     <div class="fig-inline"><a class="fig-inline-link" href="http://jac.oxfordjournals.org/content/57/4/619/F4.expansion.html"><img alt="Figure 4." src="F4.small.gif"></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a class="fig-inline-link" href="http://jac.oxfordjournals.org/content/57/4/619/F4.expansion.html">In this page</a></li>
                              <li><a target="_top" class="in-nw-vis" href="http://jac.oxfordjournals.org/content/57/4/619/F4.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="http://jac.oxfordjournals.org/powerpoint/57/4/619/F4">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label"><strong>Figure 4.</strong></span> 
                        <p id="p-31" class="first-child">Model of the mechanism of action of small-molecule inhibitors of CCR5. Nt, N-terminus.</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-32">Although this model was initially developed for AD101 and SCH-C antagonists, it is thought to be the mechanism of action of
                     all small-molecule inhibitors of CCR5. However, TAK-779, SCH-C, vicriviroc and aplaviroc have different molecular structures
                     and bind to CCR5 in different ways<sup><a id="xref-ref-48-2" class="xref-bibr" href="#ref-48">48</a></sup></p>
                  
               </div>
               <div class="section" id="sec-7">
                  <div class="section-nav"><a href="#sec-6" title="CCR5 antagonists and their mechanism of action" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-8" title="Resistance to CCR5 and CXCR4 antagonists" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>CXCR4 antagonists and their mechanism of action</h2>
                  
                  <p id="p-33">The potent antiviral activity that <strong>AMD3100</strong> shows against X4 strains has been confirmed in different <em>in vitro</em> and <em>in vivo</em> studies.<sup><a id="xref-ref-49-1" class="xref-bibr" href="#ref-49">49</a>,<a id="xref-ref-50-1" class="xref-bibr" href="#ref-50">50</a></sup> However, AnorMED, the pharmaceutical company owning this compound, re-oriented the clinical use of AMD3100, now termed Mozobil™,
                     towards stem cell mobilization for transplantation of stem cells in cancer patients (non-Hodgkin lymphoma and multiple myeloma),
                     after recognizing abnormal cardiac activity in two patients recruited in Phase Ia/IIb clinical trials. Moreover, AMD3100 did
                     not show the expected antiviral activity at the doses tested. Subsequent studies have identified derivatives which show potent
                     antiviral activity. One of these compounds <strong>AMD070</strong> shows good oral bioavailability and seems to be well tolerated.<sup><a id="xref-ref-51-1" class="xref-bibr" href="#ref-51">51</a></sup> In March of 2005, AnorMED announced the start of Phase Ib/IIa clinical trials with AMD070.
                  </p>
                  
                  <p id="p-34"><strong>KRH-1636</strong> is another CXCR4 antagonist, which shows antiviral activity similar to that of AMD3100. Studies conducted in rats showed
                     that this drug appears to be duodenally absorbable and thus is expected to be orally bioavailable.<sup><a id="xref-ref-52-1" class="xref-bibr" href="#ref-52">52</a></sup> <strong>KRH-2731</strong> is a new CXCR4 antagonist that binds to the second and third extracellular loops (ECL2 and ECL3) of CXCR4. <em>In vitro</em> studies have confirmed its potent antiviral activity against X4 and R5X4 HIV strains, which could be 10-fold higher than
                     that for AMD070.<sup><a id="xref-ref-53-1" class="xref-bibr" href="#ref-53">53</a></sup> It shows good oral bioavailability. Phase II trials are currently ongoing.
                  </p>
                  
                  <p id="p-35">The binding site for CXCR4 antagonists is located in the ECL2 of the CXCR4 co-receptor.<sup><a id="xref-ref-49-2" class="xref-bibr" href="#ref-49">49</a>,<a id="xref-ref-54-1" class="xref-bibr" href="#ref-54">54</a>,<a id="xref-ref-55-1" class="xref-bibr" href="#ref-55">55</a></sup> Due to the highly negative charge that CXCR4 exhibits on the surface, it is thought that the interactions with the HIV gp120
                     V3 loop are mainly achieved by means of electrostatic forces.<sup><a id="xref-ref-56-1" class="xref-bibr" href="#ref-56">56</a></sup></p>
                  
               </div>
               <div class="section" id="sec-8">
                  <div class="section-nav"><a href="#sec-7" title="CXCR4 antagonists and their mechanism of action" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-9" title="Fusion inhibitors and their mechanism of action" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Resistance to CCR5 and CXCR4 antagonists</h2>
                  
                  <p id="p-36">Two main resistance pathways are theoretically possible for CCR5 and CXCR4 antagonists. The first is a shift in co-receptor
                     usage and the second results from changes in HIV envelope genomic regions which allow the interaction between gp120 and the
                     co-receptor despite the presence of the inhibitor.
                  </p>
                  
                  <p id="p-37">Data available so far suggest that most CCR5 antagonist-resistant strains continue the use of the CCR5 co-receptor rather
                     than shifting to CXCR4. Furthermore, multiple mutations within different regions of HIV gp120 (V3, C2, V2, C4) account for
                     the drug-resistant phenotype.<sup><a id="xref-ref-57-1" class="xref-bibr" href="#ref-57">57</a>–<a id="xref-ref-59-1" class="xref-bibr" href="#ref-59">59</a></sup> Most resistance mutations are specific for each of the different compounds, which may hopefully limit cross-resistance. However,
                     large clinical studies are needed to prove this concept. Preliminary findings with HIV isolates resistant to maraviroc have
                     demonstrated that they remain susceptible to SCH-C, vicriviroc and aplaviroc.<sup><a id="xref-ref-60-1" class="xref-bibr" href="#ref-60">60</a></sup> In contrast, vicriviroc-resistant strains show cross-resistance to SCH-C, AD101 and RANTES derivates, most probably because
                     they share their interaction site with the CCR5 co-receptor.<sup><a id="xref-ref-59-2" class="xref-bibr" href="#ref-59">59</a></sup> In any case, CCR5 antagonist-resistant strains do not show cross-resistance with the current approved antiretrovirals, RT
                     and protease inhibitors. Nor are they cross-resistant to other entry blockers, such as CD4–gp120 binding inhibitors and enfuvirtide.<sup><a id="xref-ref-59-3" class="xref-bibr" href="#ref-59">59</a></sup></p>
                  
                  <p id="p-38">Resistance to CXCR4 antagonists is less well documented than resistance to CCR5 antagonists. Mutations in the HIV gp120 V3
                     domain seem to account for the loss of susceptibility to many of these compounds. However, mutations in other HIV gp120 regions
                     (V1, V2 and V4) have also been associated with resistance to CXCR4 antagonists, including a five amino acid deletion [codons
                     364–368 (FNSTW)] within the V4 domain.<sup><a id="xref-ref-61-1" class="xref-bibr" href="#ref-61">61</a>,<a id="xref-ref-62-1" class="xref-bibr" href="#ref-62">62</a></sup></p>
                  
                  <p id="p-39">Although preliminary results have not identified a shift in co-receptor use as the main resistance pathway for evading CCR5
                     antagonists, it will be important to closely monitor this, particularly in patients with a mixed population of R5 and X4 viruses
                     at baseline. In a Phase IIa clinical study involving the R5 inhibitor maraviroc, one patient with an R5/X4 mixture viral population
                     was inadvertently enrolled. Changes in circulating viruses were analysed during and after the maraviroc treatment. Although
                     R5 variants were suppressed during maraviroc treatment, they again became the dominant population upon treatment cessation.<sup><a id="xref-ref-63-1" class="xref-bibr" href="#ref-63">63</a></sup> However, another patient enrolled in a clinical trial with aplaviroc experienced a shift in the viral population from R5
                     to R5/X4 on day 10 of the treatment, suggesting that R5/X4 or X4 viruses could be present as minor quasispecies in some individuals
                     and become predominant following initiation of therapy with CCR5 antagonists.<sup><a id="xref-ref-64-1" class="xref-bibr" href="#ref-64">64</a></sup> The demonstration of a shift in co-receptor use from CCR5 towards CXCR4 using CCR5 antagonists could have dreadful consequences
                     in HIV disease progression, since X4 isolates tend to be more virulent than R5 viruses. On the other hand, the converse could
                     happen as well with the use of CXCR4 antagonists, in which case a shift to R5 viruses occurs.<sup><a id="xref-ref-65-1" class="xref-bibr" href="#ref-65">65</a></sup> The results from ongoing larger clinical trials with these compounds are eagerly awaited and will answer these critical questions.
                  </p>
                  
               </div>
               <div class="section" id="sec-9">
                  <div class="section-nav"><a href="#sec-8" title="Resistance to CCR5 and CXCR4 antagonists" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-10" title="Resistance to fusion inhibitors" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Fusion inhibitors and their mechanism of action</h2>
                  
                  <p id="p-40">Following the interaction between the gp120–CD4 complex and the chemokine receptor CCR5 or CXCR4, additional conformational
                     changes take place in the viral envelope that cause a shift from a non-fusogenic to a fusogenic state of the HIV gp41, which
                     ultimately drive the fusion process. The N-terminal domain of gp41 is exposed and inserted through the fusion peptide (FP)
                     into the cellular membrane. Later, gp41 experiences a structural reorganization that provokes the interaction between the
                     heptad repeat regions HR1 and HR2, forming a thermostable, six-helix bundle structure, which is critical for the viral and
                     cellular membrane fusion. The change in free energy associated with the formation of the six-helix bundle provides the force
                     necessary for the fusion pore formation, and the viral capsid enters the target cell through this process.<sup><a id="xref-ref-1-2" class="xref-bibr" href="#ref-1">1</a>,<a id="xref-ref-66-1" class="xref-bibr" href="#ref-66">66</a></sup></p>
                  
                  <p id="p-41">The antiviral properties of peptides synthesized on the basis of the amino acid sequences of HR1 and HR2 of gp41 were originally
                     recognized in the early 1990s.<sup><a id="xref-ref-67-1" class="xref-bibr" href="#ref-67">67</a>–<a id="xref-ref-69-1" class="xref-bibr" href="#ref-69">69</a></sup> DP106, which mimicked a fragment of the HR1 amino acid sequence, was the first HIV peptide inhibitor described.<sup><a id="xref-ref-67-2" class="xref-bibr" href="#ref-67">67</a></sup> In 1993, the <em>in vitro</em> potency of another peptide, DP-108, synthesized on the basis of the amino acid sequence of HR2, was demonstrated.<sup><a id="xref-ref-70-1" class="xref-bibr" href="#ref-70">70</a></sup> This molecule is currently known as T-20 or enfuvirtide.
                  </p>
                  
                  <p id="p-42"><strong>Enfuvirtide</strong> is a synthetic peptide of 36 amino acids that mimics an HR2 fragment of gp41. Its binding to the HR1 region blocks the formation
                     of the six-helix bundle structure, which is critical for the fusion process.<sup><a id="xref-ref-66-2" class="xref-bibr" href="#ref-66">66</a></sup> The clinical efficacy and safety of enfuvirtide was demonstrated in the TORO 1 and 2 clinical trials, in which the virological
                     and immunological benefits of adding enfuvirtide along with an optimized antiretroviral regimen in multidrug-experienced patients
                     was demonstrated.<sup><a id="xref-ref-71-1" class="xref-bibr" href="#ref-71">71</a>,<a id="xref-ref-72-1" class="xref-bibr" href="#ref-72">72</a></sup> Enfuvirtide was approved for the treatment of HIV infection in the year 2003.<sup><a id="xref-ref-73-1" class="xref-bibr" href="#ref-73">73</a></sup></p>
                  
                  <p id="p-43"><strong>T-1249</strong> represents a second generation of fusion inhibitors. This molecule is a 39 amino acid peptide synthesized, like enfuvirtide,
                     on the basis of the HR2 sequence. However, it overlaps a different HR1 region.<sup><a id="xref-ref-74-1" class="xref-bibr" href="#ref-74">74</a></sup> Interestingly, T-1249 was active against HIV-1 enfuvirtide-resistant strains as well as against HIV-2 and SIV.<sup><a id="xref-ref-75-1" class="xref-bibr" href="#ref-75">75</a>,<a id="xref-ref-76-1" class="xref-bibr" href="#ref-76">76</a></sup> However, the clinical development of this drug was discontinued in January 2004.
                  </p>
                  
               </div>
               <div class="section" id="sec-10">
                  <div class="section-nav"><a href="#sec-9" title="Fusion inhibitors and their mechanism of action" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-11" title="Conclusions" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Resistance to fusion inhibitors</h2>
                  
                  <p id="p-44">Early <em>in vitro</em> studies showed that enfuvirtide resistance involves the selection of changes in a three amino acid domain (positions 36–38)
                     within the HR1 region of gp41.<sup><a id="xref-ref-77-1" class="xref-bibr" href="#ref-77">77</a></sup> Subsequent results obtained in clinical studies have shown that resistance in patients receiving enfuvirtide may also be
                     due to changes expanding from codon 36 to 45 within HR1 (GIVQQQNNLL) (<a id="xref-fig-5-1" class="xref-fig" href="#F5">Figure 5</a>).<sup><a id="xref-ref-78-1" class="xref-bibr" href="#ref-78">78</a>–<a id="xref-ref-80-1" class="xref-bibr" href="#ref-80">80</a></sup> A spectrum of different mutations has been described in this amino acid region (positions 36–45), each one reducing significantly,
                     although to a different extent, the susceptibility to the drug.<sup><a id="xref-ref-1-3" class="xref-bibr" href="#ref-1">1</a>,<a id="xref-ref-81-1" class="xref-bibr" href="#ref-81">81</a></sup> Overall, enfuvirtide should be considered as a drug with a low genetic barrier for resistance. 
                     
                  </p>
                  <div id="F5" class="fig pos-float odd">
                     <div class="fig-inline"><a class="fig-inline-link" href="http://jac.oxfordjournals.org/content/57/4/619/F5.expansion.html"><img alt="Figure 5." src="F5.small.gif"></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a class="fig-inline-link" href="http://jac.oxfordjournals.org/content/57/4/619/F5.expansion.html">In this page</a></li>
                              <li><a target="_top" class="in-nw-vis" href="http://jac.oxfordjournals.org/content/57/4/619/F5.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="http://jac.oxfordjournals.org/powerpoint/57/4/619/F5">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label"><strong>Figure 5.</strong></span> 
                        <p id="p-45" class="first-child">Schematic representation of the gp41 linear structure. Enfuvirtide and T-1249 sequences mimic HR2. FP, fusion peptide; CC,
                           cysteine-cysteine; TM, transmembrane domain.
                        </p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-46">A wide range of susceptibility to enfuvirtide in viral isolates has been shown in enfuvirtide-naive patients, as well as in
                     individuals undergoing enfuvirtide therapy and harbouring apparently the same resistance mutations.<sup><a id="xref-ref-79-2" class="xref-bibr" href="#ref-79">79</a>,<a id="xref-ref-81-2" class="xref-bibr" href="#ref-81">81</a>,<a id="xref-ref-82-1" class="xref-bibr" href="#ref-82">82</a></sup> The determinants of this heterogeneity are unclear, but polymorphisms in the HR2 region of gp41 as well as changes in HR2
                     selected during enfuvirtide treatment could explain this phenomenon.<sup><a id="xref-ref-83-1" class="xref-bibr" href="#ref-83">83</a></sup> Several changes in HR2 have been recognized in patients under enfuvirtide therapy, although they do not seem to follow a
                     specific pattern. Therefore, it is difficult to conclude that changes in HR2 may influence enfuvirtide susceptibility.<sup><a id="xref-ref-81-3" class="xref-bibr" href="#ref-81">81</a>,<a id="xref-ref-84-1" class="xref-bibr" href="#ref-84">84</a></sup> However, some authors have identified specific changes in HR2 selected during enfuvirtide therapy (i.e. mutation S138A),
                     which could be secondary and/or compensatory mutations.<sup><a id="xref-ref-85-1" class="xref-bibr" href="#ref-85">85</a>,<a id="xref-ref-86-1" class="xref-bibr" href="#ref-86">86</a></sup></p>
                  
                  <p id="p-47">There is controversy regarding the impact of HIV co-receptor use on susceptibility to enfuvirtide. While some <em>in vitro</em> studies have shown that R5 strains could be more resistant to enfuvirtide,<sup><a id="xref-ref-87-1" class="xref-bibr" href="#ref-87">87</a>,<a id="xref-ref-88-1" class="xref-bibr" href="#ref-88">88</a></sup> <em>in vivo</em> studies have not found significant differences in the response to enfuvirtide therapy when comparing patients harbouring
                     R5 strains with those harbouring X4 strains.<sup><a id="xref-ref-89-1" class="xref-bibr" href="#ref-89">89</a>,<a id="xref-ref-90-1" class="xref-bibr" href="#ref-90">90</a></sup></p>
                  
                  <p id="p-48">Besides viral factors, host determinants (i.e. the level of co-receptor expression on target cells) may also influence the
                     susceptibility to enfuvirtide. In this way, the presence of high levels of CCR5 on the cellular surface might result in more
                     rapid HIV fusion, reducing the time during which HIV gp41 could be targeted by enfuvirtide. Accordingly, individuals carrying
                     Δ32–CCR5, who express low levels of CCR5, seem to respond more favourably to enfuvirtide.<sup><a id="xref-ref-88-2" class="xref-bibr" href="#ref-88">88</a></sup></p>
                  
               </div>
               <div class="section" id="sec-11">
                  <div class="section-nav"><a href="#sec-10" title="Resistance to fusion inhibitors" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-12" title="Transparency declarations" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Conclusions</h2>
                  
                  <p id="p-49">Entry inhibitors are a promising therapeutic option for HIV-infected patients carrying drug-resistant viruses. Enfuvirtide
                     is the first fusion inhibitor approved for clinical use, but many other compounds are currently in the advanced stages of
                     clinical development. The knowledge of the mechanisms of action of each of these molecules is crucial to understand and predict
                     the corresponding resistance pathways. While resistance to enfuvirtide is largely dependent on the selection of changes in
                     residues 36–45 within the gp41 HR1 region, the resistance profile for other entry inhibitors is expected to be more complex.
                     The variability of the <em>env</em> gene among the different HIV strains, in conjunction with the different structures and mechanisms of action of the whole
                     family of entry inhibitors, is the major factor responsible for this complexity. Multiple changes in different gp120 domains
                     have been associated with resistance to entry inhibitors. Moreover, it remains to be confirmed whether a shift in co-receptor
                     use might be an alternative pathway for HIV to evade drug pressure in patients exposed to CCR5 or CXCR4 antagonists.
                  </p>
                  
               </div>
               <div class="section" id="sec-12">
                  <div class="section-nav"><a href="#sec-11" title="Conclusions" class="prev-section-link"><span>Previous Section</span></a><a href="#ack-1" title="Acknowledgments" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Transparency declarations</h2>
                  
                  <p id="p-50">The authors express that they don't have any conflicts of interest, financial or otherwise, regarding this manuscript.</p>
                  
               </div>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope" itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search" href="http://jac.oxfordjournals.org/search?author1=Ver%C3%B3nica+Briz&amp;sortspec=date&amp;submit=Submit">Verónica Briz</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope" itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search" href="http://jac.oxfordjournals.org/search?author1=Eva+Poveda&amp;sortspec=date&amp;submit=Submit">Eva Poveda</a></span> and 
                     </li>
                     <li class="last" id="contrib-3"><span class="name"><a class="name-search" href="http://jac.oxfordjournals.org/search?author1=Vincent+Soriano&amp;sortspec=date&amp;submit=Submit">Vincent Soriano</a></span><a id="xref-corresp-1-1" class="xref-corresp" href="#corresp-1">*</a></li>
                  </ol><p class="affiliation-list-reveal"><a href="#" class="view-more">+</a> Author Affiliations</p>
                  <ol class="affiliation-list hideaffil">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address>Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain</address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="fn" id="corresp-1"><span class="corresp-label">*</span>Corresponding author. Tel: +34-91-4532500; Fax: +34-91-7336614; E-mail: <a href="mailto:vsoriano@dragonet.es">vsoriano@dragonet.es</a></li>
                  </ol>
                  <ul class="history-list"></ul>
               </div>
               <div class="section ack" id="ack-1">
                  <div class="section-nav"><a href="#sec-12" title="Transparency declarations" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Acknowledgments</h2>
                  
                  <p id="p-51">This work was funded in part by grants from Fundación Investigación y Educación en SIDA (IES) and Red de Investigación en
                     SIDA (RIS project 173).
                  </p>
                  
               </div>
               <ul>
                  <li class="fn" id="copyright-statement-1">© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All
                     rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
                  </li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#ack-1" title="Acknowledgments" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder">&nbsp;</div>
                  </div>
                  <h2>References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">1.</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference   1.  in text" id="ref-1">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.1">
                           <div class="cit-metadata"><cite>Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. <span class="cit-source">AIDS Rev</span> <span class="cit-pub-date">2005</span>; <span class="cit-vol">7</span>: <span class="cit-fpage">139</span>–47.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=16302461&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000232700900002&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">2.</span><a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference   2.  in text" id="ref-2">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.2">
                           <div class="cit-metadata"><cite>Dalgleish A, Beverley P, Clapham P <em>et al</em>. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. <span class="cit-source">Nature</span> <span class="cit-pub-date">1984</span>; <span class="cit-vol">312</span>: <span class="cit-fpage">763</span>–7.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1038/312763a0&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=6096719&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">3.</span><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference   3.  in text" id="ref-3">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.3">
                           <div class="cit-metadata"><cite>Klatzmann D, Champagne E, Chamaret S <em>et al</em>. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. <span class="cit-source">Nature</span> <span class="cit-pub-date">1984</span>; <span class="cit-vol">312</span>: <span class="cit-fpage">767</span>–8.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1038/312767a0&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=6083454&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">4.</span><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference   4.  in text" id="ref-4">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.4">
                           <div class="cit-metadata"><cite>Sattentau Q, Weiss R. The CD4 antigen: physiological ligand and HIV receptor. <span class="cit-source">Cell</span> <span class="cit-pub-date">1988</span>; <span class="cit-vol">52</span>, <span class="cit-fpage">631</span>–3.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1016/0092-8674(88)90397-2&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=2830988&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=A1988M623400001&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">5.</span><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference   5.  in text" id="ref-5">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.5">
                           <div class="cit-metadata"><cite>Hoxie J. Hypothetical assignment of intrachain disulfide bonds for HIV-2 and SIV envelope glycoproteins. <span class="cit-source">AIDS Res Hum Retroviruses</span> <span class="cit-pub-date">1991</span>; <span class="cit-vol">7</span>: <span class="cit-fpage">495</span>–9.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=1931228&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=A1991FU36100002&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">6.</span><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference   6.  in text" id="ref-6">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.6">
                           <div class="cit-metadata"><cite>Leonard C, Spellman M, Riddle L <em>et al</em>. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant
                                 HIV envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. <span class="cit-source">J Biol Chem</span> <span class="cit-pub-date">1990</span>; <span class="cit-vol">265</span>: <span class="cit-fpage">10373</span>–82.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jbc&amp;resid=265/18/10373" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">7.</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference   7.  in text" id="ref-7">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.7">
                           <div class="cit-metadata"><cite>Madani N, Perdigoto A, Srinivasan K <em>et al</em>. Localized changes in the gp120 envelope glycoprotein confer resistance to HIV entry inhibitors BMS-806 and #155. <span class="cit-source">J Virol</span> <span class="cit-pub-date">2004</span>; <span class="cit-vol">78</span>: <span class="cit-fpage">3742</span>–52.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=78/7/3742" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">8.</span><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference   8.  in text" id="ref-8">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.8">
                           <div class="cit-metadata"><cite>Kwong P, Wyatt R, Robinson J <em>et al</em>. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. <span class="cit-source">Nature</span> <span class="cit-pub-date">1998</span>; <span class="cit-vol">393</span>: <span class="cit-fpage">648</span>–59.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1038/31405&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=9641677&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">9.</span><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference   9.  in text" id="ref-9">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.9">
                           <div class="cit-metadata"><cite>Myszka D, Sweet R, Hensley P <em>et al</em>. Energetics of the HIV gp120-CD4 binding reaction. <span class="cit-source">Proc Natl Acad Sci USA</span> <span class="cit-pub-date">2000</span>; <span class="cit-vol">97</span>: <span class="cit-fpage">9026</span>–31.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=97/16/9026" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">10.</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference   10.  in text" id="ref-10">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.10">
                           <div class="cit-metadata"><cite>Kwong P, Wyatt R, Majeed S <em>et al</em>. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. <span class="cit-source">Structure</span> <span class="cit-pub-date">2000</span>; <span class="cit-vol">8</span>: <span class="cit-fpage">1329</span>–39.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=11188697&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">11.</span><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference   11.  in text" id="ref-11">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.11">
                           <div class="cit-metadata"><cite>Wyatt R, Kwong P, Desjardins E <em>et al</em>. The antigenic structure of the HIV gp120 envelope glycoprotein. <span class="cit-source">Nature</span> <span class="cit-pub-date">1998</span>; <span class="cit-vol">393</span>: <span class="cit-fpage">705</span>–11.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1038/31514&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=9641684&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">12.</span><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference   12.  in text" id="ref-12">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.12">
                           <div class="cit-metadata"><cite>Allaway G, Davis-Bruno K, Beaudry G <em>et al</em>. Expression and characterization of CD4-Ig2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. <span class="cit-source">AIDS Res Hum Retroviruses</span> <span class="cit-pub-date">1995</span>; <span class="cit-vol">11</span>: <span class="cit-fpage">533</span>–9.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=7576908&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=A1995RA34700001&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">13.</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference   13.  in text" id="ref-13">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.13">
                           <div class="cit-metadata"><cite>Jacobson J, Lowy I, Fletcher C <em>et al</em>. Single-dose safety, pharmacology and antiviral activity of the HIV type 1 entry inhibitor PRO 542 in HIV-infected adults.
                                 <span class="cit-source">J Infect Dis</span> <span class="cit-pub-date">2000</span>; <span class="cit-vol">182</span>: <span class="cit-fpage">326</span>–9.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jinfdis&amp;resid=182/1/326" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">14.</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference   14.  in text" id="ref-14">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.14">
                           <div class="cit-metadata"><cite>Nagashima K, Thompson D, Rosenfield S <em>et al</em>. HIV type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell fusion. <span class="cit-source">J Infect Dis</span> <span class="cit-pub-date">2001</span>; <span class="cit-vol">183</span>: <span class="cit-fpage">1121</span>–5.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jinfdis&amp;resid=183/7/1121" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">15.</span><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference   15.  in text" id="ref-15">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.15">
                           <div class="cit-metadata"><cite>Moore J, Sattentau Q, Klasse P <em>et al</em>. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of
                                 HIV-1 and HIV infection of CD4+ cells. <span class="cit-source">J Virol</span> <span class="cit-pub-date">1992</span>; <span class="cit-vol">66</span>: <span class="cit-fpage">4784</span>–93.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=66/8/4784" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">16.</span><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference   16.  in text" id="ref-16">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.16">
                           <div class="cit-metadata"><cite>Kuritzkes D, Jacobson J, Powderly W <em>et al</em>. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. <span class="cit-source">J Infect Dis</span> <span class="cit-pub-date">2004</span>; <span class="cit-vol">189</span>: <span class="cit-fpage">286</span>–91.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jinfdis&amp;resid=189/2/286" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">17.</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference   17.  in text" id="ref-17">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.17">
                           <div class="cit-metadata"><cite>Reeves J, Piefer A. Emerging drug targets for antiretroviral therapy. <span class="cit-source">Drugs</span> <span class="cit-pub-date">2005</span>; <span class="cit-vol">65</span>: <span class="cit-fpage">1747</span>–66.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.2165/00003495-200565130-00002&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=16114975&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000232023900002&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">18.</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference   18.  in text" id="ref-18">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.18">
                           <div class="cit-metadata"><cite>Vermeire K, Bell T, Chi H <em>et al</em>. The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the
                                 CD4 receptor. <span class="cit-source">Mol Pharmacol</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">63</span>: <span class="cit-fpage">203</span>–10.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=molpharm&amp;resid=63/1/203" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">19.</span><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference   19.  in text" id="ref-19">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.19">
                           <div class="cit-metadata"><cite>Vermeire K, Zhang Y, Princen K <em>et al</em>. CADA inhibits HIV and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. <span class="cit-source">Virology</span> <span class="cit-pub-date">2002</span>; <span class="cit-vol">302</span>: <span class="cit-fpage">342</span>–53.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1006/viro.2002.1624&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=12441078&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000179140400014&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">20.</span><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference   20.  in text" id="ref-20">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.20">
                           <div class="cit-metadata"><cite>Lin P-F, Blair W, Wang T <em>et al</em>. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding<span class="cit-source">. Proc Natl Acad Sci USA</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">100</span>: <span class="cit-fpage">11013</span>–8.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=100/19/11013" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">21.</span><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference   21.  in text" id="ref-21">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.21">
                           <div class="cit-metadata"><cite>Guo Q, Ho H-T, Dicker I <em>et al</em>. Biochemical and genetic characterizations of a novel HIV type 1 inhibitor that blocks gp120-CD4 interactions. <span class="cit-source">J Virol</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">77</span>: <span class="cit-fpage">10528</span>–36.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=77/19/10528" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">22.</span><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference   22.  in text" id="ref-22">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.22">
                           <div class="cit-metadata unstructured">Lin P-H, Robinson B, Gong Y <em>et al</em>. Identification and characterization of a novel inhibitor of HIV-1 entry-I: virology and resistance. In: <em>Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 24 February 2002</em>. Abstract 9. USA.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">23.</span><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference   23.  in text" id="ref-23">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.23">
                           <div class="cit-metadata unstructured">Lin P, Guo K, Fridell R <em>et al</em>. Identification and characterization of a novel inhibitor of HIV-1 entry-II: mechanism of action. In: <em>Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 24 February 2002</em>. Abstract 10. USA.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">24.</span><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference   24.  in text" id="ref-24">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.24">
                           <div class="cit-metadata"><cite>Wang J, Williams R, Lin P. A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding.
                                 <span class="cit-source">Curr Pharm Des</span> <span class="cit-pub-date">2004</span>; <span class="cit-vol">10</span>: <span class="cit-fpage">1785</span>–93.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.2174/1381612043384565&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=15180540&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000221784200009&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">25.</span><a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference   25.  in text" id="ref-25">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.25">
                           <div class="cit-metadata"><cite>Veazey R, Klasse P, Schader S <em>et al</em>. Protection of macaques from vaginal SHIV challenges by vaginally delivered inhibitors of virus-cell fusion. <span class="cit-source">Nature</span> <span class="cit-pub-date">2005</span>; <span class="cit-vol">438</span>: <span class="cit-fpage">99</span>–102.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1038/nature04055&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=16258536&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">26.</span><a class="rev-xref-ref" href="#xref-ref-26-1" title="View reference   26.  in text" id="ref-26">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.26">
                           <div class="cit-metadata"><cite>Moore P, Cilliers T, Mornis L. Predicted genotypic resistance to the novel entry inhibitor, BMS378806, among HIV-1 isolates
                                 of subtypes A to G. <span class="cit-source">AIDS</span> <span class="cit-pub-date">2004</span>; <span class="cit-vol">18</span>: <span class="cit-fpage">2327</span>–30.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1097/00002030-200411190-00015&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=15577547&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000225656900014&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">27.</span><a class="rev-xref-ref" href="#xref-ref-27-1" title="View reference   27.  in text" id="ref-27">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.27">
                           <div class="cit-metadata"><cite>Comier E, Dragic T. The crown and stem of the V3 loop play distinct roles in HIV type 1 envelope glycoprotein interactions
                                 with the CCR5 coreceptor. <span class="cit-source">J Virol</span> <span class="cit-pub-date">2002</span>; <span class="cit-vol">76</span>: <span class="cit-fpage">8953</span>–7.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=76/17/8953" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">28.</span><a class="rev-xref-ref" href="#xref-ref-28-1" title="View reference   28.  in text" id="ref-28">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.28">
                           <div class="cit-metadata"><cite>Berger E, Doms R, Fenyö E <em>et al</em>. A new classification for HIV-1. <span class="cit-source">Nature</span> <span class="cit-pub-date">1998</span>; <span class="cit-vol">391</span>: <span class="cit-fpage">240</span>.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1038/34571&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=9440686&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">29.</span><a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference   29.  in text" id="ref-29">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.29">
                           <div class="cit-metadata"><cite>Dragic T, Trkola A, Lin S <em>et al</em>. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and HIV type 1 entry. <span class="cit-source">J Virol</span> <span class="cit-pub-date">1998</span>; <span class="cit-vol">72</span>: <span class="cit-fpage">279</span>–85.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=72/1/279" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">30.</span><a class="rev-xref-ref" href="#xref-ref-30-1" title="View reference   30.  in text" id="ref-30">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.30">
                           <div class="cit-metadata"><cite>Wu L, LaRosa G, Kassam N <em>et al</em>. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for
                                 chemokine binding. <span class="cit-source">J Exp Med</span> <span class="cit-pub-date">1997</span>; <span class="cit-vol">186</span>: <span class="cit-fpage">1373</span>–81.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jem&amp;resid=186/8/1373" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">31.</span><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference   31.  in text" id="ref-31">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.31">
                           <div class="cit-metadata"><cite>Picard L, Wilkinson D, McKnight A <em>et al</em>. Role of the amino-terminal extracellular domain of CXCR4 in HIV type 1 entry. <span class="cit-source">Virology</span> <span class="cit-pub-date">1997</span>; <span class="cit-vol">231</span>: <span class="cit-fpage">105</span>–11.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1006/viro.1997.8506&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=9143308&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=A1997WW95700013&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">32.</span><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference   32.  in text" id="ref-32">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.32">
                           <div class="cit-metadata"><cite>Baba M, Nishimura O, Kanzaki N <em>et al</em>. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. <span class="cit-source">Proc Natl Acad Sci USA</span> <span class="cit-pub-date">1999</span>; <span class="cit-vol">96</span>: <span class="cit-fpage">5698</span>–703.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=96/10/5698" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">33.</span><a class="rev-xref-ref" href="#xref-ref-33-1" title="View reference   33.  in text" id="ref-33">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.33">
                           <div class="cit-metadata"><cite>Dragic T, Trkola A, Thompson D <em>et al</em>. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. <span class="cit-source">Proc Natl Acad Sci USA</span> <span class="cit-pub-date">2000</span>; <span class="cit-vol">97</span>: <span class="cit-fpage">5639</span>–44.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=97/10/5639" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">34.</span><a class="rev-xref-ref" href="#xref-ref-34-1" title="View reference   34.  in text" id="ref-34">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.34">
                           <div class="cit-metadata unstructured">Lizawa Y, Kanzaki N, Takashima K <em>et al</em>. Anti-HIV-1 activity of TAK-220, a small molecule CCR5 antagonist. In: <em>Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA</em>, <em>10–14 February 2003</em>. Abstract 11. USA.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">35.</span><a class="rev-xref-ref" href="#xref-ref-35-1" title="View reference   35.  in text" id="ref-35">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.35">
                           <div class="cit-metadata unstructured">Baba M, Kanzaki N, Miyake H <em>et al</em>. RAK-652, a novel small molecule inhibitor of CCR5 antagonist with potent anti-HIV-1 activity. In: <em>Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 22–25 February 2005</em>. Abstract 541. USA.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">36.</span><a class="rev-xref-ref" href="#xref-ref-36-1" title="View reference   36.  in text" id="ref-36">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.36">
                           <div class="cit-metadata"><cite>Trkola A, Ketas T, Nagashima K <em>et al</em>. Potent, broad-spectrum inhibition of HIV type 1 by the CCR5 monoclonal antibody PRO 140. <span class="cit-source">J Virol</span> <span class="cit-pub-date">2001</span>; <span class="cit-vol">75</span>: <span class="cit-fpage">579</span>–88.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=75/2/579" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">37.</span><a class="rev-xref-ref" href="#xref-ref-37-1" title="View reference   37.  in text" id="ref-37">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.37">
                           <div class="cit-metadata unstructured">Reynes J, Rouzier R, Kanouni T <em>et al</em>. SCH C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1 infected subjects. In: <em>Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA</em>, <em>24–28 February 2002</em>. Abstract 1. USA.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">38.</span><a class="rev-xref-ref" href="#xref-ref-38-1" title="View reference   38.  in text" id="ref-38">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.38">
                           <div class="cit-metadata"><cite>Strizki J, Tremblay C, Xu S <em>et al</em>. Discovery and characterization of vicriviroc (SCH 417690), a novel CCR5 antagonist with potent activity against human immunodeficiency
                                 virus type 1. <span class="cit-source">Antimicrob Agents and Chemother</span> <span class="cit-pub-date">2005</span>; <span class="cit-vol">49</span>: <span class="cit-fpage">4991</span>–9.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">39.</span><a class="rev-xref-ref" href="#xref-ref-39-1" title="View reference   39.  in text" id="ref-39">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.39">
                           <div class="cit-metadata"><cite>Tsamis F, Gavrilov S, Kajumo F <em>et al</em>. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-31125 and SCH-350581 inhibit HIV type 1 entry.
                                 <span class="cit-source">J Virol</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">77</span>: <span class="cit-fpage">5201</span>–8.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=77/9/5201" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">40.</span><a class="rev-xref-ref" href="#xref-ref-40-1" title="View reference   40.  in text" id="ref-40">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.40">
                           <div class="cit-metadata unstructured">Dunkle L, Keung A, Sansone A <em>et al</em>. Vicriviroc is a novel, potent CCR5 inhibitor with pharmaceutic, pharmacokinetic and pharmacodynamic (PK/PD) properties that
                              support once daily dosing. In: <em>First International Workshop on Targeting HIV Entry, Bethesda MD, 2–3 December 2005.</em> Abstract 13. USA.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">41.</span><a class="rev-xref-ref" href="#xref-ref-41-1" title="View reference   41.  in text" id="ref-41">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.41">
                           <div class="cit-metadata unstructured">Hitchcock C. The discovery and exploratory development of UK-427,857: a novel CCR5 antagonist for the treatment of HIV. In:
                              <em>Thirteenth International Symposium on HIV and Emerging Infectious Diseases</em>, <em>Toulon, France, 3–5 June 2004</em>, Abstract OP 4.5.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">42.</span><a class="rev-xref-ref" href="#xref-ref-42-1" title="View reference   42.  in text" id="ref-42">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.42">
                           <div class="cit-metadata"><cite>De Clercq E. New approaches toward anti-HIV chemotherapy. <span class="cit-source">J Med Chem</span> <span class="cit-pub-date">2005</span>; <span class="cit-vol">10</span>; <span class="cit-fpage">241</span>–74.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">43.</span><a class="rev-xref-ref" href="#xref-ref-43-1" title="View reference   43.  in text" id="ref-43">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.43">
                           <div class="cit-metadata unstructured">Fätkenheuer G, Pozniak A, Johnson M <em>et al</em>. Evaluation of dosing frequency and food effect on viral load reduction during short-term monotherapy with UK-427,857, a
                              novel CCR5 antagonist. In: <em>Fifteenth International AIDS Conference, Bangkok, Thailand, 11–16 July 2004</em>. Abstract B4489.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">44.</span><a class="rev-xref-ref" href="#xref-ref-44-1" title="View reference   44.  in text" id="ref-44">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.44">
                           <div class="cit-metadata"><cite>Castonguay L, Weng Y, Adolfsen W <em>et al</em>. Binding of 2-aryl-4(piperidin-1yl)butanmines and 1, 3, 4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guide
                                 mutagenesis study of the binding pocket. <span class="cit-source">Biochemistry</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">42</span>: <span class="cit-fpage">1544</span>–50.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1021/bi026639s&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=12578367&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">45.</span><a class="rev-xref-ref" href="#xref-ref-45-1" title="View reference   45.  in text" id="ref-45">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.45">
                           <div class="cit-metadata"><cite>Maeda K, Nakata H, Miyakawa T <em>et al</em>. Spirodiketopiperazine-based CCR5 inhibitor, which preserves CC chemokine/CCR5 interactions and exerts potent activity against
                                 R5 HIV type 1 <em>in vitro</em>. <span class="cit-source">J Virol</span> <span class="cit-pub-date">2004</span>; <span class="cit-vol">78</span>: <span class="cit-fpage">8654</span>–62.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=78/16/8654" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">46.</span><a class="rev-xref-ref" href="#xref-ref-46-1" title="View reference   46.  in text" id="ref-46">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.46">
                           <div class="cit-metadata unstructured">Nakata H, Maeda K, Kawano Y <em>et al</em>. Potent <em>in vivo</em> anti-R5HIV effects of AK602, a novel spirodiketopiperazine (SPD)-containing HIV-specific CCR5 inhibitor, in hu-PBMC-NOD-mice.
                              In: <em>Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 10–14 February 2003</em>. Abstract 564a. USA.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">47.</span><a class="rev-xref-ref" href="#xref-ref-47-1" title="View reference   47.  in text" id="ref-47">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.47">
                           <div class="cit-metadata unstructured">Maeda K, Ogata H, Harada S <em>et al</em>. Determination of binding sites of a unique CCR5 inhibitor AK602 /ONO-4128/ GW873140 on human CCR5. In: <em>Eleventh Conference on Retroviruses and Opportunistic Infections</em>, <em>San Francisco, CA, 8–11 February 2004</em>. Abstract 540. USA.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">48.</span><a class="rev-xref-ref" href="#xref-ref-48-1" title="View reference   48.  in text" id="ref-48">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.48">
                           <div class="cit-metadata"><cite>Watson C, Jenkinson S, Kazmierski W <em>et al</em>. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. <span class="cit-source">Mol Pharmacol</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">67</span>: <span class="cit-fpage">1268</span>–82.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">49.</span><a class="rev-xref-ref" href="#xref-ref-49-1" title="View reference   49.  in text" id="ref-49">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.49">
                           <div class="cit-metadata"><cite>Donzella G, Schols D, Lin S <em>et al</em>. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. <span class="cit-source">Nat Med</span> <span class="cit-pub-date">1998</span>; <span class="cit-vol">4</span>: <span class="cit-fpage">72</span>–7.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1038/nm0198-072&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=9427609&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000072249700037&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">50.</span><a class="rev-xref-ref" href="#xref-ref-50-1" title="View reference   50.  in text" id="ref-50">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.50">
                           <div class="cit-metadata unstructured">Schols D, Claes S, De Clercq E <em>et al</em>. AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 virus levels in humans. In: <em>Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 24–28 February 2002</em>. Abstract 2. USA
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">51.</span><a class="rev-xref-ref" href="#xref-ref-51-1" title="View reference   51.  in text" id="ref-51">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.51">
                           <div class="cit-metadata unstructured">Schols D, Claes S, Hatse S <em>et al</em>. Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist. In: <em>Sixteenth International Conference on Antiviral Research, Savannah, GA, 27 April to 1 May 2003.</em> Abstract A39. USA.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">52.</span><a class="rev-xref-ref" href="#xref-ref-52-1" title="View reference   52.  in text" id="ref-52">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.52">
                           <div class="cit-metadata"><cite>Ichiyama K, Yokoyama-Kumakura S, Tanaka Y <em>et al</em>. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity.
                                 <span class="cit-source">Proc Natl Acad Sci USA</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">100</span>: <span class="cit-fpage">4185</span>–90.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=100/7/4185" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">53.</span><a class="rev-xref-ref" href="#xref-ref-53-1" title="View reference   53.  in text" id="ref-53">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.53">
                           <div class="cit-metadata unstructured">Murakami E, Yoshida A, Kumakura S <em>et al</em>. KRH-2731: an orally bioavailable CXCR4 antagonist <em>in vivo</em>. In: <em>Fifteenth International AIDS Conference</em>, <em>Bangkok, Thailand, 11–16 July 2004</em>. Abstract LbA01.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">54.</span><a class="rev-xref-ref" href="#xref-ref-54-1" title="View reference   54.  in text" id="ref-54">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.54">
                           <div class="cit-metadata"><cite>Murakami T, Nakajima T, Koyanagi Y <em>et al</em>. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. <span class="cit-source">J Exp Med</span> <span class="cit-pub-date">1997</span>; <span class="cit-vol">186</span>: <span class="cit-fpage">1389</span>–93.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jem&amp;resid=186/8/1389" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">55.</span><a class="rev-xref-ref" href="#xref-ref-55-1" title="View reference   55.  in text" id="ref-55">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.55">
                           <div class="cit-metadata"><cite>Labrosse B, Brelot N, Heveker N <em>et al</em>. Determinants for sensitivity of HIV coreceptor CXCR4 to the bicyclam AMD3100. <span class="cit-source">J Virol</span> <span class="cit-pub-date">1998</span>; <span class="cit-vol">72</span>: <span class="cit-fpage">6381</span>–8.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=72/8/6381" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">56.</span><a class="rev-xref-ref" href="#xref-ref-56-1" title="View reference   56.  in text" id="ref-56">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.56">
                           <div class="cit-metadata"><cite>Brelot A, Heveker N, Pleskoff O <em>et al</em>. Role of the first and third extracellular domains of CXCR4 in HIV coreceptor activity. <span class="cit-source">J Virol</span> <span class="cit-pub-date">1997</span>; <span class="cit-vol">71</span>: <span class="cit-fpage">4744</span>–51.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=71/6/4744" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">57.</span><a class="rev-xref-ref" href="#xref-ref-57-1" title="View reference   57.  in text" id="ref-57">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.57">
                           <div class="cit-metadata"><cite>Trkola A, Kuhmann S, Strizki J <em>et al</em>. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. <span class="cit-source">Proc Natl Acad Sci USA</span> <span class="cit-pub-date">2002</span>; <span class="cit-vol">99</span>: <span class="cit-fpage">395</span>–400.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=99/1/395" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">58.</span><a class="rev-xref-ref" href="#xref-ref-58-1" title="View reference   58.  in text" id="ref-58">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.58">
                           <div class="cit-metadata"><cite>Kuhmann S, Pugach P, Kunstman K <em>et al</em>. Genetic and phenotypic analyses of HIV type 1 escape from a small-molecule CCR5 inhibitor. <span class="cit-source">J Virol</span> <span class="cit-pub-date">2004</span>; <span class="cit-vol">78</span>: <span class="cit-fpage">2790</span>–807.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=78/6/2790" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">59.</span><a class="rev-xref-ref" href="#xref-ref-59-1" title="View reference   59.  in text" id="ref-59">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.59">
                           <div class="cit-metadata"><cite>Marozsan A, Kuhmann S, Morgan T <em>et al</em>. Generation and properties of a HIV type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). <span class="cit-source">Virology</span> <span class="cit-pub-date">2005</span>; <span class="cit-vol">338</span>: <span class="cit-fpage">182</span>–99.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1016/j.virol.2005.04.035&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=15935415&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000230470400017&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">60.</span><a class="rev-xref-ref" href="#xref-ref-60-1" title="View reference   60.  in text" id="ref-60">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.60">
                           <div class="cit-metadata"><cite>Westby M, Mori J, Smith-Burchnell D <em>et al</em>. Maraviroc (UK-427,857)-resistant HIV-1 variants, selected by serial passage, are sensitive to CCR5 antagonists and T-20.
                                 <span class="cit-source">Antivir Ther</span> <span class="cit-pub-date">2005</span>; <span class="cit-vol">10</span>: <span class="cit-fpage">S72</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">61.</span><a class="rev-xref-ref" href="#xref-ref-61-1" title="View reference   61.  in text" id="ref-61">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.61">
                           <div class="cit-metadata"><cite>De Vreese K, Kofler-Mongold V, Leutgeb C <em>et al</em>. The molecular target of bicyclams, potent inhibitors of HIV replication. <span class="cit-source">J Virol</span> <span class="cit-pub-date">1996</span>; <span class="cit-vol">70</span>: <span class="cit-fpage">689</span>–96.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=70/2/689" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">62.</span><a class="rev-xref-ref" href="#xref-ref-62-1" title="View reference   62.  in text" id="ref-62">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.62">
                           <div class="cit-metadata"><cite>Schols D, Este J, Cabrera C <em>et al</em>. T-cell-line tropic HIV type 1 that is made resistant to stromal cell-derived factor 1α contains mutations in the envelope
                                 gp120 but does not show a switch in coreceptor use. <span class="cit-source">J Virol</span> <span class="cit-pub-date">1998</span>; <span class="cit-vol">72</span>: <span class="cit-fpage">4032</span>–7.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=72/5/4032" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">63.</span><a class="rev-xref-ref" href="#xref-ref-63-1" title="View reference   63.  in text" id="ref-63">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.63">
                           <div class="cit-metadata unstructured">Westby M, Whitcomb J, Huang W <em>et al</em>. Reversible predominance of CXCR4 using variants in a non-responsive dual tropic patient receiving the CCR5 antagonist UK-427,857.
                              In: <em>Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 8–11 February 2004</em>. Abstract 538. USA.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">64.</span><a class="rev-xref-ref" href="#xref-ref-64-1" title="View reference   64.  in text" id="ref-64">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.64">
                           <div class="cit-metadata"><cite>Kitrinos K, LaBranche C, Stanhope M <em>et al</em>. Clonal analysis detects pre-existing R5X4-tropic virus in patient demonstrating populations-level tropism shift on 873140
                                 monotherapy. <span class="cit-source">Antivir Ther</span> <span class="cit-pub-date">2005</span>; <span class="cit-vol">10</span>: <span class="cit-fpage">S68</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">65.</span><a class="rev-xref-ref" href="#xref-ref-65-1" title="View reference   65.  in text" id="ref-65">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.65">
                           <div class="cit-metadata"><cite>Este J, Cabrera C, Blanco J <em>et al</em>. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing
                                 phenotype by blockade of CXCR4. <span class="cit-source">J Virol</span> <span class="cit-pub-date">1999</span>; <span class="cit-vol">73</span>: <span class="cit-fpage">5577</span>–85.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=73/7/5577" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">66.</span><a class="rev-xref-ref" href="#xref-ref-66-1" title="View reference   66.  in text" id="ref-66">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.66">
                           <div class="cit-metadata"><cite>Weiss C. HIV-1 gp41: Mediator of fusion and target for inhibition. <span class="cit-source">AIDS Rev</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">5</span>: <span class="cit-fpage">214</span>–21.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=15012000&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">67.</span><a class="rev-xref-ref" href="#xref-ref-67-1" title="View reference   67.  in text" id="ref-67">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.67">
                           <div class="cit-metadata"><cite>Wild C, Oas T, McDanal D <em>et al</em>. A synthetic peptide inhibitor of HIV replication: correlation between solution structure and viral inhibition. <span class="cit-source">Proc Natl Acad Sci USA</span> <span class="cit-pub-date">1992</span>; <span class="cit-vol">89</span>: <span class="cit-fpage">10537</span>–41.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=89/21/10537" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">68.</span><a class="rev-xref-ref" href="#xref-ref-68-1" title="View reference   68.  in text" id="ref-68">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.68">
                           <div class="cit-metadata"><cite>Wild C, Shugars D, Greenwell T <em>et al</em>. Peptides corresponding to a predictive alpha-helical domain of HIV type 1 are potent inhibitors of virus infection. <span class="cit-source">Proc Natl Acad Sci USA</span> <span class="cit-pub-date">1994</span>; <span class="cit-vol">91</span>: <span class="cit-fpage">9770</span>–4.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=91/21/9770" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">69.</span><a class="rev-xref-ref" href="#xref-ref-69-1" title="View reference   69.  in text" id="ref-69">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.69">
                           <div class="cit-metadata"><cite>Jiang S, Li K, Strik N <em>et al</em>. A. HIV-1 inhibition by a peptide. <span class="cit-source">Nature</span> <span class="cit-pub-date">1993</span>; <span class="cit-vol">365</span>: <span class="cit-fpage">113</span>.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=8371754&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">70.</span><a class="rev-xref-ref" href="#xref-ref-70-1" title="View reference   70.  in text" id="ref-70">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.70">
                           <div class="cit-metadata"><cite>Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus mediated cell-cell fusion.
                                 <span class="cit-source">AIDS Res Hum Retroviruses</span> <span class="cit-pub-date">1993</span>; <span class="cit-vol">9</span>: <span class="cit-fpage">1051</span>–3.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=8312047&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=A1993MK13000001&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">71.</span><a class="rev-xref-ref" href="#xref-ref-71-1" title="View reference   71.  in text" id="ref-71">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.71">
                           <div class="cit-metadata"><cite>Lazzarin A, Clotet B, Cooper D <em>et al</em>. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. <span class="cit-source">N Engl J Med</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">348</span>: <span class="cit-fpage">2186</span>–95.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1056/NEJMoa035211&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=12773645&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000183134700004&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">72.</span><a class="rev-xref-ref" href="#xref-ref-72-1" title="View reference   72.  in text" id="ref-72">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.72">
                           <div class="cit-metadata"><cite>Lalezari J, Henry M, O'Hearn M <em>et al</em>. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. <span class="cit-source">N Engl J Med</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">348</span>: <span class="cit-fpage">2175</span>–85.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1056/NEJMoa035026&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=12637625&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000183134700003&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">73.</span><a class="rev-xref-ref" href="#xref-ref-73-1" title="View reference   73.  in text" id="ref-73">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.73">
                           <div class="cit-metadata"><cite>Robertson D. US FDA approves new class of HIV therapeutics. <span class="cit-source">Nat Biotechnol</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">21</span>: <span class="cit-fpage">470</span>–1.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1038/nbt0503-470&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=12721558&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000182660300005&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">74.</span><a class="rev-xref-ref" href="#xref-ref-74-1" title="View reference   74.  in text" id="ref-74">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.74">
                           <div class="cit-metadata"><cite>Kilby J, Eron J. Novel therapies based on mechanisms of HIV-1 cell entry. <span class="cit-source">N Engl J Med</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">348</span>: <span class="cit-fpage">2228</span>–38.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1056/NEJMra022812&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=12773651&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000183134700010&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">75.</span><a class="rev-xref-ref" href="#xref-ref-75-1" title="View reference   75.  in text" id="ref-75">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.75">
                           <div class="cit-metadata unstructured">Miralles G, Lalezari J, Bellos N <em>et al</em>. T-1249 demonstrates potent antiviral activity over 10-day dosing in most patients who have failed a regimen containing enfuvirtide:
                              planned interim analysis of T1249-102, a phase I/II study. In: <em>Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 10–14 February 2003</em>. Abstract 14Ib.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">76.</span><a class="rev-xref-ref" href="#xref-ref-76-1" title="View reference   76.  in text" id="ref-76">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.76">
                           <div class="cit-metadata"><cite>Melby T, Zhang Y, Cammack N <em>et al</em>. Genotypic and phenotypic evolution of virus envelope through 48 weeks of T-1249 treatment in the T1249-105 study. <span class="cit-source">Antivir Ther</span> <span class="cit-pub-date">2005</span>; <span class="cit-vol">10</span>: <span class="cit-fpage">S76</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">77.</span><a class="rev-xref-ref" href="#xref-ref-77-1" title="View reference   77.  in text" id="ref-77">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.77">
                           <div class="cit-metadata"><cite>Rimsky L, Shugars D, Matthews T. Determinants of HIV type 1 resistance to gp41-derived inhibitors peptides. <span class="cit-source">J Virol</span> <span class="cit-pub-date">1998</span>; <span class="cit-vol">78</span>: <span class="cit-fpage">986</span>–93.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">78.</span><a class="rev-xref-ref" href="#xref-ref-78-1" title="View reference   78.  in text" id="ref-78">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.78">
                           <div class="cit-metadata"><cite>Wei X, Decker J, Liu H <em>et al</em>. Emergence of resistant HIV-1 in patients receiving fusion inhibitor (T-20) monotherapy. <span class="cit-source">Antimicrob Agents Chemother</span> <span class="cit-pub-date">2002</span>; <span class="cit-vol">46</span>: <span class="cit-fpage">1896</span>–905.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=aac&amp;resid=46/6/1896" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">79.</span><a class="rev-xref-ref" href="#xref-ref-79-1" title="View reference   79.  in text" id="ref-79">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.79">
                           <div class="cit-metadata"><cite>Sista P, Melby T, Davison D <em>et al</em>. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1
                                 isolates. <span class="cit-source">AIDS</span> <span class="cit-pub-date">2004</span>; <span class="cit-vol">18</span>: <span class="cit-fpage">1787</span>–94.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1097/00002030-200409030-00007&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=15316339&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000223667900007&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">80.</span><a class="rev-xref-ref" href="#xref-ref-80-1" title="View reference   80.  in text" id="ref-80">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.80">
                           <div class="cit-metadata"><cite>Poveda E, Rodés B, Labernardière JL <em>et al</em>. Evolution of genotypic and phenotypic resistance to enfuvirtide in HIV-infected patients experiencing prolonged virologic
                                 failure. <span class="cit-source">J Med Virol</span> <span class="cit-pub-date">2004</span>; <span class="cit-vol">74</span>: <span class="cit-fpage">21</span>–8.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1002/jmv.20141&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=15258964&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000222956400004&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">81.</span><a class="rev-xref-ref" href="#xref-ref-81-1" title="View reference   81.  in text" id="ref-81">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.81">
                           <div class="cit-metadata"><cite>Poveda E, Rodés B, Lebel-Binay S <em>et al</em>. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. <span class="cit-source">J Clin Virol</span> <span class="cit-pub-date">2005</span>; <span class="cit-vol">34</span>: <span class="cit-fpage">295</span>–301.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/external-ref?access_num=10.1016/j.jcv.2005.02.004&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=16286053&amp;link_type=MED" class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="http://jac.oxfordjournals.org/external-ref?access_num=000233769700009&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">82.</span><a class="rev-xref-ref" href="#xref-ref-82-1" title="View reference   82.  in text" id="ref-82">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.82">
                           <div class="cit-metadata"><cite>Labrosse B, Labernardière J, Dam E <em>et al</em>. Baseline susceptibility of primary HIV-1 to entry inhibitors. <span class="cit-source">J Virol</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">77</span>: <span class="cit-fpage">1610</span>–3.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">83.</span><a class="rev-xref-ref" href="#xref-ref-83-1" title="View reference   83.  in text" id="ref-83">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.83">
                           <div class="cit-metadata"><cite>Stanfield-Oakley S, Jefrey J, McDanal C <em>et al</em>. Determinants of susceptibility to enfuvirtide map to gp41 in enfuvirtide-naive HIV-1. <span class="cit-source">Antivir Ther</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">8</span>: <span class="cit-fpage">S22</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">84.</span><a class="rev-xref-ref" href="#xref-ref-84-1" title="View reference   84.  in text" id="ref-84">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.84">
                           <div class="cit-metadata unstructured">Xu L, Pozniak A, Wildfire A <em>et al</em>. Evolution of HR1 and HR2 mutations in HIV-1 gp41 associated with long-term enfuvirtide therapy. In: <em>Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 8–11 February 2004</em>. Abstract 659. USA.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">85.</span><a class="rev-xref-ref" href="#xref-ref-85-1" title="View reference   85.  in text" id="ref-85">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.85">
                           <div class="cit-metadata unstructured">Cabrera C, García E, Marfil S <em>et al</em>. Resistance to enfuvirtide (ENF) proceeds through selection of mutations in gp41 and gp120. In: <em>Fourteenth International HIV Drug Resistance Workshop, Quebec, Canada, 7–11 June 2005</em>. Abstract 167.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">86.</span><a class="rev-xref-ref" href="#xref-ref-86-1" title="View reference   86.  in text" id="ref-86">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.86">
                           <div class="cit-metadata"><cite>Xu L, Pozniak A, Wildfire A <em>et al</em>. Emergence and evolution of enfuvirtide following long-term therapy involves heptad repeat 2 mutations within gp41. <span class="cit-source">Antimicrob Agents Chemother</span> <span class="cit-pub-date">2005</span>; <span class="cit-vol">49</span>: <span class="cit-fpage">1113</span>–9.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=aac&amp;resid=49/3/1113" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">87.</span><a class="rev-xref-ref" href="#xref-ref-87-1" title="View reference   87.  in text" id="ref-87">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.87">
                           <div class="cit-metadata"><cite>Derdeyn C, Decker J, Sfakianos J <em>et al</em>. Sensitivity of HIV type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41
                                 and is consistently modulated by gp120 interactions with the coreceptor. <span class="cit-source">J Virol</span> <span class="cit-pub-date">2001</span>; <span class="cit-vol">75</span>: <span class="cit-fpage">8605</span>–14.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=75/18/8605" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">88.</span><a class="rev-xref-ref" href="#xref-ref-88-1" title="View reference   88.  in text" id="ref-88">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.88">
                           <div class="cit-metadata"><cite>Reeves J, Gallo S, Ahmad N <em>et al</em>. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
                                 <span class="cit-source">Proc Natl Acad Sci USA</span> <span class="cit-pub-date">2002</span>; <span class="cit-vol">99</span>: <span class="cit-fpage">16249</span>–54.</cite></div>
                           <div class="cit-extra"><a href="http://jac.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=99/25/16249" class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">89.</span><a class="rev-xref-ref" href="#xref-ref-89-1" title="View reference   89.  in text" id="ref-89">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.89">
                           <div class="cit-metadata unstructured">Whitcomb J, Huang W, Fransen S <em>et al</em>. Analysis of baseline enfuvirtide (T-20) susceptibility and co-receptor tropism in two phase III study populations. In: <em>Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 10–14 February 2003</em>. Abstract 557. USA.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">90.</span><a class="rev-xref-ref" href="#xref-ref-90-1" title="View reference   90.  in text" id="ref-90">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-57.4.619.90">
                           <div class="cit-metadata"><cite>Su C, Heilek-Snyder G, Fenger D <em>et al</em>. The relationship between susceptibility to enfuvirtide of baseline viral recombinants and polymorphisms in the env region
                                 of R5-tropic HIV-1. <span class="cit-source">Antivir Ther</span> <span class="cit-pub-date">2003</span>; <span class="cit-vol">8</span>: <span class="cit-fpage">S59</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div><span id="related-urls"></span><div xmlns="http://www.w3.org/1999/xhtml" id="cited-by"><h2>Articles citing this article</h2><ul class="cited-by-list"><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">HIV gp120 H375 Is Unique to HIV-1 Subtype CRF01_AE and Confers Strong Resistance to the Entry Inhibitor BMS-599793, a Candidate Microbicide Drug </span> <cite><abbr title="Antimicrobial Agents and Chemotherapy" class="site-title">Antimicrob. Agents Chemother.</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2012<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">56</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>8<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">4257</span><span class="cit-sep">-</span><span class="cit-last-page">4267</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck aac;56/8/4257 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://aac.asm.org/cgi/content/abstract/56/8/4257" rel="abstract">Abstract</a></li><li><a href="http://aac.asm.org/cgi/content/full/56/8/4257" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://aac.asm.org/cgi/reprint/56/8/4257" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients </span> <cite><abbr title="Journal of Infectious Diseases" class="site-title">The Journal of Infectious Disease</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2011<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">203</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>2<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">237</span><span class="cit-sep">-</span><span class="cit-last-page">245</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck jinfdis;203/2/237 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://jid.oxfordjournals.org/cgi/content/abstract/203/2/237" rel="abstract">Abstract</a></li><li><a href="http://jid.oxfordjournals.org/cgi/content/full/203/2/237" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://jid.oxfordjournals.org/cgi/reprint/203/2/237" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors </span> <cite><abbr title="Journal of General Virology" class="site-title">J. Gen. Virol.</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2010<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">91</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>12<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">2965</span><span class="cit-sep">-</span><span class="cit-last-page">2973</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck vir;91/12/2965 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://vir.sgmjournals.org/cgi/content/abstract/91/12/2965" rel="abstract">Abstract</a></li><li><a href="http://vir.sgmjournals.org/cgi/content/full/91/12/2965" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://vir.sgmjournals.org/cgi/reprint/91/12/2965" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection </span> <cite><abbr title="Journal of Antimicrobial Chemotherapy" class="site-title">J Antimicrob Chemother</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2010<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">65</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>9<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">1839</span><span class="cit-sep">-</span><span class="cit-last-page">1841</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck jac;65/9/1839 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://jac.oxfordjournals.org/cgi/content/abstract/65/9/1839" rel="abstract">Abstract</a></li><li><a href="http://jac.oxfordjournals.org/cgi/content/full/65/9/1839" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://jac.oxfordjournals.org/cgi/reprint/65/9/1839" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">Long-Lasting Enfuvirtide Carrier Pentasaccharide Conjugates with Potent Anti-Human Immunodeficiency Virus Type 1 Activity </span> <cite><abbr title="Antimicrobial Agents and Chemotherapy" class="site-title">Antimicrob. Agents Chemother.</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2010<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">54</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>1<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">134</span><span class="cit-sep">-</span><span class="cit-last-page">142</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck aac;54/1/134 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://aac.asm.org/cgi/content/abstract/54/1/134" rel="abstract">Abstract</a></li><li><a href="http://aac.asm.org/cgi/content/full/54/1/134" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://aac.asm.org/cgi/reprint/54/1/134" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">Human immunodeficiency virus downregulates podocyte apoE expression </span> <cite><abbr title="American Journal of Physiology - Renal Physiology" class="site-title">Am. J. Physiol. Renal Physiol.</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2009<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">297</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>3<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">F653</span><span class="cit-sep">-</span><span class="cit-last-page">F661</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck ajprenal;297/3/F653 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://ajprenal.physiology.org/cgi/content/abstract/297/3/F653" rel="abstract">Abstract</a></li><li><a href="http://ajprenal.physiology.org/cgi/content/full/297/3/F653" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://ajprenal.physiology.org/cgi/reprint/297/3/F653" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients </span> <cite><abbr title="Journal of Antimicrobial Chemotherapy" class="site-title">J Antimicrob Chemother</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2009<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">63</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>6<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">1087</span><span class="cit-sep">-</span><span class="cit-last-page">1096</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck jac;63/6/1087 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://jac.oxfordjournals.org/cgi/content/abstract/63/6/1087" rel="abstract">Abstract</a></li><li><a href="http://jac.oxfordjournals.org/cgi/content/full/63/6/1087" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://jac.oxfordjournals.org/cgi/reprint/63/6/1087" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists </span> <cite><abbr title="Journal of Antimicrobial Chemotherapy" class="site-title">J Antimicrob Chemother</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2009<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">63</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>5<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">1006</span><span class="cit-sep">-</span><span class="cit-last-page">1010</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck jac;63/5/1006 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://jac.oxfordjournals.org/cgi/content/abstract/63/5/1006" rel="abstract">Abstract</a></li><li><a href="http://jac.oxfordjournals.org/cgi/content/full/63/5/1006" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://jac.oxfordjournals.org/cgi/reprint/63/5/1006" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">Baseline Resistance of Primary Human Immunodeficiency Virus Type 1 Strains to the CXCR4 Inhibitor AMD3100 </span> <cite><abbr title="Journal of Virology" class="site-title">J. Virol.</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2008<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">82</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>23<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">11695</span><span class="cit-sep">-</span><span class="cit-last-page">11704</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck jvi;82/23/11695 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://jvi.asm.org/cgi/content/abstract/82/23/11695" rel="abstract">Abstract</a></li><li><a href="http://jvi.asm.org/cgi/content/full/82/23/11695" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://jvi.asm.org/cgi/reprint/82/23/11695" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">Heterocyclic Compounds That Inhibit Rev-RRE Function and Human Immunodeficiency Virus Type 1 Replication </span> <cite><abbr title="Antimicrobial Agents and Chemotherapy" class="site-title">Antimicrob. Agents Chemother.</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2008<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">52</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>9<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">3169</span><span class="cit-sep">-</span><span class="cit-last-page">3179</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck aac;52/9/3169 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://aac.asm.org/cgi/content/abstract/52/9/3169" rel="abstract">Abstract</a></li><li><a href="http://aac.asm.org/cgi/content/full/52/9/3169" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://aac.asm.org/cgi/reprint/52/9/3169" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE {varepsilon}4/{varepsilon}4 genotype accelerates HIV disease progression </span> <cite><abbr title="PNAS" class="site-title">Proc. Natl. Acad. Sci. USA</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2008<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">105</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>25<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">8718</span><span class="cit-sep">-</span><span class="cit-last-page">8723</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck pnas;105/25/8718 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://www.pnas.org/cgi/content/abstract/105/25/8718" rel="abstract">Abstract</a></li><li><a href="http://www.pnas.org/cgi/content/full/105/25/8718" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://www.pnas.org/cgi/reprint/105/25/8718" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">Effect of Genital Ulcer Disease on HIV-1 Coreceptor Expression in the Female Genital Tract </span> <cite><abbr title="Journal of Infectious Diseases" class="site-title">The Journal of Infectious Disease</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2007<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">196</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>10<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">1509</span><span class="cit-sep">-</span><span class="cit-last-page">1516</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck jinfdis;196/10/1509 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://jid.oxfordjournals.org/cgi/content/abstract/196/10/1509" rel="abstract">Abstract</a></li><li><a href="http://jid.oxfordjournals.org/cgi/content/full/196/10/1509" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://jid.oxfordjournals.org/cgi/reprint/196/10/1509" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">Human Immunodeficiency Virus Type 1 Variants Resistant to First- and Second-Version Fusion Inhibitors and Cytopathic in Ex Vivo Human Lymphoid Tissue </span> <cite><abbr title="Journal of Virology" class="site-title">J. Virol.</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2007<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">81</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>12<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">6563</span><span class="cit-sep">-</span><span class="cit-last-page">6572</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck jvi;81/12/6563 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://jvi.asm.org/cgi/content/abstract/81/12/6563" rel="abstract">Abstract</a></li><li><a href="http://jvi.asm.org/cgi/content/full/81/12/6563" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://jvi.asm.org/cgi/reprint/81/12/6563" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors </span> <cite><abbr title="Journal of Virology" class="site-title">J. Virol.</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2007<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">81</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>7<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">3240</span><span class="cit-sep">-</span><span class="cit-last-page">3250</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck jvi;81/7/3240 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://jvi.asm.org/cgi/content/abstract/81/7/3240" rel="abstract">Abstract</a></li><li><a href="http://jvi.asm.org/cgi/content/full/81/7/3240" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://jvi.asm.org/cgi/reprint/81/7/3240" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li><li class="cit"><div class="cit-metadata"><span class="cit-first-element cit-title">Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism </span> <cite><abbr title="Antimicrobial Agents and Chemotherapy" class="site-title">Antimicrob. Agents Chemother.</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2007<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">51</span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>2<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">566</span><span class="cit-sep">-</span><span class="cit-last-page">575</span> </span></cite>  </div><div class="cit-extra"><span class="accesscheck aac;51/2/566 abstract,full,reprint"></span> <ul class="cit-views"><li class="first-item"><a href="http://aac.asm.org/cgi/content/abstract/51/2/566" rel="abstract">Abstract</a></li><li><a href="http://aac.asm.org/cgi/content/full/51/2/566" rel="full-text">Full Text (HTML)</a></li><li class="last-item"><a href="http://aac.asm.org/cgi/reprint/51/2/566" rel="full-text.pdf">Full Text (PDF)</a></li></ul>  </div> </li></ul></div></div>
         <div style="height: 19359px;" id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="http://jac.oxfordjournals.org/content/57/4/609.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="http://jac.oxfordjournals.org/content/57/4/628.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="http://jac.oxfordjournals.org/content/57/4.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="Journal of Antimicrobial Chemotherapy" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">J. Antimicrob. Chemother.</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">

                                    (April 2006) 
                                    </span>
                                 
                                 <span class="slug-vol">

                                    57
                                    </span><span class="slug-issue">

                                    (4):
                                    </span><span class="slug-pages">

                                    619-627.
                                    </span>
                                 <span class="slug-doi-wrapper">

                                    
                                    doi:
                                    
                                    <span title="10.1093/jac/dkl027" class="slug-doi">10.1093/jac/dkl027</span>
                                    </span>
                                 </cite>
                              
                              
                              <span class="slug-metadata-note ahead-of-print">

                                 
                                 First published online:
                                 
                                 <span class="slug-ahead-of-print-date">February 7, 2006</span>
                                 </span>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="http://jac.oxfordjournals.org/content/57/4/619.abstract" rel="view-abstract">Abstract</a><span class="viewspecificaccesscheck jac;57/4/619 abstract free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="viewspecificaccesscheck jac;57/4/619 full free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="http://jac.oxfordjournals.org/content/57/4/619.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="viewspecificaccesscheck jac;57/4/619 reprint free">Free</span></li>
                        <li class="cb-versions">
                           <div><span id="pap-all-versions-label">All Versions of this Article:</span><ol class="version-list">
                                 <li><a href="http://jac.oxfordjournals.org/content/early/2006/02/07/jac.dkl027">dkl027v1</a></li>
                                 <li class="current-li"><span>57/4/619</span> <span class="current-version">most recent</span></li>
                              </ol>
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><a href="#" class="collapse-toggle"><span class="view-more">-</span> <span>Classifications</span></a></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search" href="http://jac.oxfordjournals.org/search?tocsectionid=Reviews&amp;sortspec=date&amp;submit=Submit">Review</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><a href="#" class="collapse-toggle"><span class="view-more">-</span> <span>Services</span></a></h4>
                     <ol>
                        <li class="alert-link icon-link"><a href="http://jac.oxfordjournals.org/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jac;57/4/619&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jac.oxfordjournals.org/content/57/4/619.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="http://jac.oxfordjournals.org/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=57/4/619&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jac.oxfordjournals.org/content/57/4/619.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="http://jac.oxfordjournals.org/search?qbe=jac;dkl027&amp;citation=Briz%20et%20al.%2057%20%284%29:%20619&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a xmlns="http://www.w3.org/1999/xhtml" href="http://jac.oxfordjournals.org/external-ref?access_num=jac;57/4/619&amp;link_type=ISI_RELATEDRECORDS">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="http://jac.oxfordjournals.org/external-ref?access_num=16464888&amp;link_type=MED_NBRS" class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="http://jac.oxfordjournals.org/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jac;57/4/619">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="http://jac.oxfordjournals.org/citmgr?gca=jac;57/4/619">Download citation</a></li>
                        <li><a class="request-permissions" href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jac&amp;title=HIV%20entry%20inhibitors%3A%20mechanisms%20of%20action%20and%20resistance%20pathways%3A%20&amp;publicationDate=April%202006&amp;author=Ver%C3%B3nica%20Briz%2C%20Eva%20Poveda%2C%20Vincent%20Soriano&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjac%2Fdkl027&amp;volumeNum=57&amp;issueNum=4&amp;startPage=619&amp;endPage=627&amp;orderBeanReset=true" target="_top">Request Permissions</a></li>
                        <li><a class="disclaimer" href="http://www.oxfordjournals.org/our_journals/jac/disclaimer.html">Disclaimer</a></li>
                     </ol>
                  </div>
                  <div class="cb-section default-closed collapsed" id="cb-art-cit">
                     <h4 class="cb-section-header"><a href="#" class="collapse-toggle"><span class="view-more">+</span> <span>Citing Articles</span></a></h4>
                     <ol style="display: none;">
                        <li class="hw-citing-link"><a href="#cited-by">View citing article information</a></li>
                        <li><a title="[opens in a new window]" target="_top" href="http://jac.oxfordjournals.org/cgi/crossref-forward-links/57/4/619" rel="external-nw" id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a xmlns="http://www.w3.org/1999/xhtml" class="scopus-link" href="http://jac.oxfordjournals.org/external-ref?link_type=SCOPUS_CITING&amp;scopus-path=http://www.scopus.com/scopus/inward/citedby.url&amp;nvp=partnerID%3Dc9DrA512&amp;nvp=rel%3DR6.0.0&amp;nvp=eid%3D2-s2.0-33645116573&amp;nvp=md5%3D4b128c103a7b33e1e7e124da636b6311">Citing articles via Scopus <span class="scopus-count">(94)</span></a></li>
                        <li><a xmlns="http://www.w3.org/1999/xhtml" href="http://jac.oxfordjournals.org/external-ref?access_num=jac;57/4/619&amp;link_type=ISI_CITING&amp;external_url=http%3A%2F%2Fgateway.webofknowledge.com%2Fgateway%2FGateway.cgi%3FGWVersion%3D2%26SrcApp%3DPARTNER_APP%26SrcAuth%3Dstanwire%26KeyUT%3D000236105100004%26DestLinkType%3DCitingArticles%26DestApp%3DWOS_CPL%26UsrCustomerID%3D269fc60adb004b0b719031a97aedf5e9">Citing articles via Web of Science (80)</a></li>
                        <li><a href="http://jac.oxfordjournals.org/external-ref?access_num=http://jac.oxfordjournals.org/content/57/4/619.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section default-closed collapsed" id="cb-art-gs">
                     <h4 class="cb-section-header"><a href="#" class="collapse-toggle"><span class="view-more">+</span> <span>Google Scholar</span></a></h4>
                     <ol style="display: none;">
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3ABriz%20author%3AV.%22" class="cb-art-gs-auth author-link">Articles by  Briz, V.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3ASoriano%20author%3AV.%22" class="cb-art-gs-auth author-link">Articles by  Soriano, V.</a></li>
                        <li class="cb-art-gs-rel similar-link"><a href="http://jac.oxfordjournals.org/external-ref?access_num=http://jac.oxfordjournals.org/content/57/4/619.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section default-closed collapsed" id="cb-art-pm">
                     <h4 class="cb-section-header"><a href="#" class="collapse-toggle"><span class="view-more">+</span> <span>PubMed</span></a></h4>
                     <ol style="display: none;">
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="http://jac.oxfordjournals.org/external-ref?access_num=16464888&amp;link_type=PUBMED" class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="http://jac.oxfordjournals.org/external-ref?access_num=Briz%20V&amp;link_type=AUTHORSEARCH" class="cb-art-pm-auth author-link">Articles by  Briz, V.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="http://jac.oxfordjournals.org/external-ref?access_num=Poveda%20E&amp;link_type=AUTHORSEARCH" class="cb-art-pm-auth author-link">Articles by  Poveda, E.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="http://jac.oxfordjournals.org/external-ref?access_num=Soriano%20V&amp;link_type=AUTHORSEARCH" class="cb-art-pm-auth author-link">Articles by  Soriano, V.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section default-closed collapsed nodata" id="cb-art-rel">
                     <h4 class="cb-section-header"><a href="#" class="collapse-toggle"><span class="view-more">+</span> <span>Related Content</span></a></h4>
                     <ol style="display: none;">
                        <li class="nodata"><div id="cb-loaded-related-urls-none">No related web pages</div></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><a href="#" class="collapse-toggle"><span class="view-more">-</span> <span>Share</span></a></h4>
                     <ol>
                        <li><a title="email this" href="http://jac.oxfordjournals.org/email?gca=jac;57/4/619&amp;current-view-path=/content/57/4/619.full"></a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a target="_BLANK" href="http://jac.oxfordjournals.org/external-ref?tag_url=http://jac.oxfordjournals.org/cgi/content/long/57/4/619&amp;title=HIV%20entry%20inhibitors%3A%20mechanisms%20of%20action%20and%20resistance%20pathways+--+Briz%20et%20al.%2057%20%284%29%3A%20619+--+&amp;doi=10.1093/jac/dkl027&amp;link_type=CITEULIKE"><img src="citeulike.gif" alt="Add to CiteULike" title="CiteULike"></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a target="_BLANK" href="http://jac.oxfordjournals.org/external-ref?tag_url=http://jac.oxfordjournals.org/cgi/content/long/57/4/619&amp;title=HIV%20entry%20inhibitors%3A%20mechanisms%20of%20action%20and%20resistance%20pathways+--+Briz%20et%20al.%2057%20%284%29%3A%20619+--+&amp;doi=10.1093/jac/dkl027&amp;link_type=DEL_ICIO_US"><img src="delicious.gif" alt="Add to Delicious" title="Delicious"></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a title="[opens in a new window]" target="_BLANK" href="http://jac.oxfordjournals.org/external-ref?tag_url=http://jac.oxfordjournals.org/cgi/content/short/57/4/619&amp;title=HIV%20entry%20inhibitors%3A%20mechanisms%20of%20action%20and%20resistance%20pathways+--+Briz%20et%20al.%2057%20%284%29%3A%20619+--+&amp;doi=10.1093/jac/dkl027&amp;link_type=FACEBOOK" class="sb-facebook" rel="external-nw"><img src="facebook.gif" alt="Add to Facebook" title="Facebook"></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><div id="___plusone_0" style="text-indent: 0px; margin: 0px; padding: 0px; background: none repeat ; 0% transparent; border-style: none; float: none; line-height: normal; font-size: 1px; vertical-align: baseline; display: inline-block; width: 24px; height: 15px;"><iframe title="+1" data-gapiattached="true" allowtransparency="true" src="619_2.html" name="I0_1369665818585" id="I0_1369665818585" vspace="0" tabindex="0" style="position: static; top: 0px; width: 24px; margin: 0px; border-style: none; left: 0px; visibility: visible; height: 15px;" marginwidth="0" marginheight="0" hspace="0" frameborder="0" scrolling="no" width="100%"></iframe></div><a style="display: none;" target="_BLANK" href="http://jac.oxfordjournals.org/external-ref?tag_url=http://jac.oxfordjournals.org/cgi/content/long/57/4/619&amp;title=HIV%20entry%20inhibitors%3A%20mechanisms%20of%20action%20and%20resistance%20pathways+--+Briz%20et%20al.%2057%20%284%29%3A%20619+--+&amp;doi=10.1093/jac/dkl027&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="googleplus.jpg" alt="Add to Google+" title="Google+"></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a target="_BLANK" href="http://jac.oxfordjournals.org/external-ref?tag_url=http://jac.oxfordjournals.org/cgi/content/long/57/4/619&amp;title=HIV%20entry%20inhibitors%3A%20mechanisms%20of%20action%20and%20resistance%20pathways+--+Briz%20et%20al.%2057%20%284%29%3A%20619+--+&amp;doi=10.1093/jac/dkl027&amp;link_type=MENDELEY"><img src="mendeley.gif" alt="Add to Mendeley" title="Mendeley"></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a target="_BLANK" href="http://jac.oxfordjournals.org/external-ref?tag_url=http://jac.oxfordjournals.org/cgi/content/long/57/4/619&amp;title=HIV%20entry%20inhibitors%3A%20mechanisms%20of%20action%20and%20resistance%20pathways+--+Briz%20et%20al.%2057%20%284%29%3A%20619+--+&amp;doi=10.1093/jac/dkl027&amp;link_type=TWITTER"><img src="twitter.gif" alt="Add to Twitter" title="Twitter"></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="http://jac.oxfordjournals.org/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-1">Introduction</a></li>
                        <li><a href="#sec-2">CD4–gp120 binding</a></li>
                        <li><a href="#sec-3">CD4–gp120 binding inhibitors and their mechanism of action</a></li>
                        <li><a href="#sec-4">Resistance to CD4–gp120 inhibitors</a></li>
                        <li><a href="#sec-5">gp120–co-receptor interaction</a></li>
                        <li><a href="#sec-6">CCR5 antagonists and their mechanism of action</a></li>
                        <li><a href="#sec-7">CXCR4 antagonists and their mechanism of action</a></li>
                        <li><a href="#sec-8">Resistance to CCR5 and CXCR4 antagonists</a></li>
                        <li><a href="#sec-9">Fusion inhibitors and their mechanism of action</a></li>
                        <li><a href="#sec-10">Resistance to fusion inhibitors</a></li>
                        <li><a href="#sec-11">Conclusions</a></li>
                        <li><a href="#sec-12">Transparency declarations</a></li>
                        <li><a href="#ack-1">Acknowledgments</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
            <div class="content-box" id="article-cb-main">
               
               <div class="cb-contents">
                  
                  <div class="cb-section collapsible default-open" id="cb-art-bn">
                     
                     <h4 class="cb-section-header"><a href="#" class="collapse-toggle"><span class="view-more">-</span> 
                        <span>People also read [Beta]</span>
                        
                     </a></h4>
                     
                     <ul>
                        <li>
                           
                           <div id="bnArticleRecs"><h4 class="cb-contents-header">
<span style="margin-top: 10px;"></span>
</h4><ol style="padding-right: 5px;">
<li>
<div id="bn_g_resultbnArticleRecs_1" class="bn_g_result bn_g_result" style="margin: 0px auto; padding: 0px;">
<div class="bn_g_result_title" style="margin: 0px auto; padding: 0px 5px 4px 0px;">
<a class="bn_g_result_link" baynote_req="ArticlePage" baynote_guide="NextStepMatch" baynote_bnrank="1" href="http://jac.oxfordjournals.org/cgi/doi/10.1093/jac/dkn292">Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection<div class="bn_mouseoverdiv">
<span class="bn_journaltitle"><b>Journal of Antimicrobial Chemotherapy</b> - 2008</span>
<br>
<span class="bn_authorslist">Borrás-Blasco, J.; Navarro-Ruiz, A.; Borrás, C.; Casterá, E.</span>
<br>
<span class="bn_viewCount">24 readers also viewed this
                     </span>
</div>
</a>
</div>
</div>
<div id="bn_g_resultbnArticleRecs_2" class="bn_g_result bn_g_result" style="margin: 0px auto; padding: 0px;">
<div class="bn_g_result_title" style="margin: 0px auto; padding: 0px 5px 4px 0px;">
<a class="bn_g_result_link" baynote_req="ArticlePage" baynote_guide="NextStepMatch" baynote_bnrank="2" href="http://jac.oxfordjournals.org/cgi/doi/10.1093/jac/dkq261">Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection<div class="bn_mouseoverdiv">
<span class="bn_journaltitle"><b>Journal of Antimicrobial Chemotherapy</b> - 2010</span>
<br>
<span class="bn_authorslist">Bruno, Christopher J.; Jacobson, Jeffrey M.</span>
<br>
<span class="bn_viewCount">14 readers also viewed this
                     </span>
</div>
</a>
</div>
</div>
<div id="bn_g_resultbnArticleRecs_3" class="bn_g_result bn_g_result" style="margin: 0px auto; padding: 0px;">
<div class="bn_g_result_title" style="margin: 0px auto; padding: 0px 5px 4px 0px;">
<a class="bn_g_result_link" baynote_req="ArticlePage" baynote_guide="NextStepMatch" baynote_bnrank="3" href="http://jac.oxfordjournals.org/cgi/doi/10.1093/jac/dkh161">Clinical perspective of fusion inhibitors for treatment of HIV<div class="bn_mouseoverdiv">
<span class="bn_journaltitle"><b>Journal of Antimicrobial Chemotherapy</b> - 2004</span>
<br>
<span class="bn_authorslist">Rockstroh, J. K.; Mauss, S.</span>
<br>
<span class="bn_viewCount">0 readers also viewed this
                     </span>
</div>
</a>
</div>
</div>
</li>
</ol>
</div>
                           
                        </li>
                        <li>
                           
                           <p id="bnHelp">
                              <a href="http://www.oxfordjournals.org/our_journals/help.html">What's this?</a>
                              
                           </p>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               
            </div>
            
            
         <div style="display: block;" id="docked-nav" class="dockblock"><div class="content-box" id="docked-cb"><div class="cb-contents"><h3>This Article</h3><div class="cb-section cb-slug"><ol id="docked-slug"><li><div id="slugline">
                              
                              <cite>
                                 <abbr title="Journal of Antimicrobial Chemotherapy" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">J. Antimicrob. Chemother.</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">

                                    (April 2006) 
                                    </span>
                                 
                                 <span class="slug-vol">

                                    57
                                    </span><span class="slug-issue">

                                    (4):
                                    </span><span class="slug-pages">

                                    619-627.
                                    </span>
                                 <span class="slug-doi-wrapper">

                                    
                                    doi:
                                    
                                    <span title="10.1093/jac/dkl027" class="slug-doi">10.1093/jac/dkl027</span>
                                    </span>
                                 </cite>
                              
                              
                              <span class="slug-metadata-note ahead-of-print">

                                 
                                 First published online:
                                 
                                 <span class="slug-ahead-of-print-date">February 7, 2006</span>
                                 </span>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div></li></ol></div><div class="cb-section"><ol id="docked-nav-views"><li class="abstract-view-link primary"><a href="http://jac.oxfordjournals.org/content/57/4/619.abstract" rel="view-abstract">Abstract</a><span class="viewspecificaccesscheck jac;57/4/619 abstract free">Free</span></li><li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="viewspecificaccesscheck jac;57/4/619 full free">Free</span></li><li class="notice full-text-pdf-view-link"><a href="http://jac.oxfordjournals.org/content/57/4/619.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="viewspecificaccesscheck jac;57/4/619 reprint free">Free</span></li><li class="cb-versions">
                           <div><span id="pap-all-versions-label">All Versions of this Article:</span><ol class="version-list">
                                 <li><a href="http://jac.oxfordjournals.org/content/early/2006/02/07/jac.dkl027">dkl027v1</a></li>
                                 <li class="current-li"><span>57/4/619</span> <span class="current-version">most recent</span></li>
                              </ol>
                           </div>
                        </li></ol></div></div></div><div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-1">Introduction</a></li>
                        <li><a href="#sec-2">CD4–gp120 binding</a></li>
                        <li><a href="#sec-3">CD4–gp120 binding inhibitors and their mechanism of action</a></li>
                        <li><a href="#sec-4">Resistance to CD4–gp120 inhibitors</a></li>
                        <li><a href="#sec-5">gp120–co-receptor interaction</a></li>
                        <li><a href="#sec-6">CCR5 antagonists and their mechanism of action</a></li>
                        <li><a href="#sec-7">CXCR4 antagonists and their mechanism of action</a></li>
                        <li><a href="#sec-8">Resistance to CCR5 and CXCR4 antagonists</a></li>
                        <li><a href="#sec-9">Fusion inhibitors and their mechanism of action</a></li>
                        <li><a href="#sec-10">Resistance to fusion inhibitors</a></li>
                        <li><a href="#sec-11">Conclusions</a></li>
                        <li><a href="#sec-12">Transparency declarations</a></li>
                        <li><a href="#ack-1">Acknowledgments</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div></div></div>
         <div style="height: 19359px;" id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="http://jac.oxfordjournals.org/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" name="fulltext" id="header-qs-input" type="text">
                     <input name="submit" value="yes" type="hidden">
                     <input class="inline_button" alt="Go" src="go.gif" type="image">
                     
                     <div class="adv-search-link"><a href="http://jac.oxfordjournals.org/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="http://jac.oxfordjournals.org/content/current"><span>
                                 		  <span class="current-issue-date">

                                    June 2013
                                    </span><span class="toc-citation-volume">

                                    
                                    68
                                    </span><span class="toc-citation-issue">(6)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="http://jac.oxfordjournals.org/content/current"><img src="6.cover.gif" alt="Journal of Antimicrobial Chemotherapy" id="cover"></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="http://jac.oxfordjournals.org/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/jac/about.html" title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://jac.oxfordjournals.org/content/by/section/Leading%20article" title="Free leading articles">Free leading articles</a>
                           
                        </li>
                        <li>
                           <a href="http://jac.oxfordjournals.org/content/by/section/Editorials" title="Free Editorials">Free Editorials</a>
                           
                        </li>
                        <li>
                           <a href="http://jac.oxfordjournals.org/supplements.dtl" title="JAC Supplements">JAC Supplements</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html" title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="http://www.publicationethics.org/" title="This journal is a member of the Committee on Publication Ethics">This journal is a member of the Committee on Publication Ethics</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Published on behalf of</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.bsac.org.uk/" title="The British Society for Antimicrobial Chemotherapy">The British Society for Antimicrobial Chemotherapy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor:  5.068</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <div class="contact">
                        
                        <div class="name">Prof Alan P. Johnson</div>
                        
                        <div class="clear"></div>
                        
                     </div>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/jac/editorial_board.html" title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/jac/for_authors/" title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/jac/for_authors/online_submission.html" title="Online submission instructions">Online submission instructions</a>
                           
                        </li>
                        <li>
                           <a href="http://mc.manuscriptcentral.com/oup/jac" title="Submit Now!">Submit Now!</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html" title="Self-archiving policy">Self-archiving policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/">
                        <img alt="Open access options for authors – visit Oxford Open" src="oxford_open_small.gif">
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="pmc-logo.gif">
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://jac.oxfordjournals.org/cgi/alerts/etoc" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="http://jac.oxfordjournals.org/cgi/alerts/etoc" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jac.oxfordjournals.org/help/citetrack" title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="http://jac.oxfordjournals.org/rss" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/supplements.html" title="Supplements">Supplements</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1" src="619_3.html" class="resize_ad yhkfnaqsgqmkflxzouey" frameborder="0" height="0" scrolling="no" width="0"></iframe>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300", "MED00460"];</script>
               </div>
            
            <div class="most-links-box ">
               
               <div class="most-header">
                  
                  <h3>Most</h3><ul class="most-headings"><li class="most-cur-sel"><a href="#">Most Read</a></li><li><a href="#">Most Cited</a></li></ul>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jac.oxfordjournals.org/cgi/content/short/65/suppl_3/iii25?rss=1&amp;amp;ssource=mfr">Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria</a></li>
                           <li><a href="http://jac.oxfordjournals.org/cgi/content/short/66/suppl_2/ii11?rss=1&amp;amp;ssource=mfr">Surviving the first hours in sepsis: getting the basics right (an intensivist's perspective)</a></li>
                           <li><a href="http://jac.oxfordjournals.org/cgi/content/short/47/5/565?rss=1&amp;amp;ssource=mfr">Antibacterial activity of essential oils and their major constituents against respiratory tract pathogens by gaseous contact</a></li>
                           <li><a href="http://jac.oxfordjournals.org/cgi/content/short/48/suppl_1/5?rss=1&amp;amp;ssource=mfr">Determination of minimum inhibitory concentrations</a></li>
                           <li class="last-item"><a href="http://jac.oxfordjournals.org/cgi/content/short/49/1/25?rss=1&amp;amp;ssource=mfr">Factors impacting on the problem of antibiotic resistance</a></li>
                        </ol>
                        	    <a href="http://jac.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jac.oxfordjournals.org/cgi/content/short/40/1/135?rss=1&amp;amp;ssource=mfc">Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility</a></li>
                           <li><a href="http://jac.oxfordjournals.org/cgi/content/short/59/2/165?rss=1&amp;amp;ssource=mfc">CTX-M: changing the face of ESBLs in Europe</a></li>
                           <li><a href="http://jac.oxfordjournals.org/cgi/content/short/48/suppl_1/5?rss=1&amp;amp;ssource=mfc">Determination of minimum inhibitory concentrations</a></li>
                           <li><a href="http://jac.oxfordjournals.org/cgi/content/short/52/1/1?rss=1&amp;amp;ssource=mfc">Synergy, antagonism, and what the chequerboard puts between them</a></li>
                           <li class="last-item"><a href="http://jac.oxfordjournals.org/cgi/content/short/61/2/273?rss=1&amp;amp;ssource=mfc">Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15</a></li>
                        </ol>
                        	  <a href="http://jac.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom" src="619_4.html" class="resize_ad yhkfnaqsgqmkflxzouey" frameborder="0" height="0" scrolling="no" width="0"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2091 - Print ISSN 0305-7453</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a>&nbsp;
               <span>2013</span>&nbsp;
               <a xmlns="http://schema.highwire.org/Site/Branding/Venice" href="http://www.bsac.org.uk/">British Society for Antimicrobial Chemotherapy</a> 
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input src="go_001.gif" alt="Go" class="inline_button" type="image">
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript" src="oup.cookiepolicy.pack.js" defer="defer"></script>
         <script type="text/javascript" src="hw-publisher-baynote.js" defer="defer"></script>
         <script defer="defer" src="jquery-ui.min.js" type="text/javascript"></script>
         <script defer="defer" src="jcarousellite.js" type="text/javascript"></script>
         <script defer="defer" src="pf_oiunderbarinit.js" type="text/javascript"></script>
         <script defer="defer" src="underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">

    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <script type="text/javascript">

        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script src="ga.js" type="text/javascript"></script><script type="text/javascript">

        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   
<div id="fancybox-tmp"></div><div id="fancybox-loading"><div></div></div><div id="fancybox-overlay"></div><div id="fancybox-wrap"><div id="fancybox-outer"><div class="fancybox-bg" id="fancybox-bg-n"></div><div class="fancybox-bg" id="fancybox-bg-ne"></div><div class="fancybox-bg" id="fancybox-bg-e"></div><div class="fancybox-bg" id="fancybox-bg-se"></div><div class="fancybox-bg" id="fancybox-bg-s"></div><div class="fancybox-bg" id="fancybox-bg-sw"></div><div class="fancybox-bg" id="fancybox-bg-w"></div><div class="fancybox-bg" id="fancybox-bg-nw"></div><div id="fancybox-content"></div><a id="fancybox-close"></a><div id="fancybox-title"></div><a href="javascript:;" id="fancybox-left"><span class="fancy-ico" id="fancybox-left-ico"></span></a><a href="javascript:;" id="fancybox-right"><span class="fancy-ico" id="fancybox-right-ico"></span></a></div></div><img style="display: none;" src="listener2"><img style="display: none;" src="listener2_001.dat"><div aria-labelledby="ui-dialog-title-underbar-wrapper" role="dialog" tabindex="-1" class="ui-dialog ui-widget ui-widget-content ui-corner-all " style="display: block; position: absolute; overflow: hidden; z-index: 1001; outline: 0px none; height: auto; width: 100%; left: 0px;"><div style="-moz-user-select: none; display: none;" unselectable="on" class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span style="-moz-user-select: none;" unselectable="on" id="ui-dialog-title-underbar-wrapper" class="ui-dialog-title">&nbsp;</span><a style="-moz-user-select: none;" unselectable="on" role="button" class="ui-dialog-titlebar-close ui-corner-all" href="#"><span style="-moz-user-select: none;" unselectable="on" class="ui-icon ui-icon-closethick">close</span></a></div><div class="ui-dialog-content ui-widget-content" style="display: block; height: auto; min-height: 121px; width: auto;" id="underbar-wrapper"><input id="hiddenColumns" type="hidden"><input id="hidArrCols" type="hidden"><input id="hidTotalColumns" type="hidden"><a style="display: none;" href="http://jac.oxfordjournals.org/content/57/4/undefined" target="_top" id="underbar-related" onclick="checkOpenURL(event);">See all related content</a><div style="display: none;" id="underbar-error">You must provide text in order to perform the search&nbsp;&nbsp;&nbsp;</div><div class="underbar-header" id="underbar-header"><div id="underbar-logo-cover"><img src="oi-logo.gif" alt="oi-logo" class="underbar-logoIndex" height="25" width="92"><label for="about the index" class="underbar-aboutLbl">About the Index</label><input style="display: none;" id="underbar-reveal-hide" name="underbar-reveal-hide" value="hide me" onclick="closeOIUnderbar();" type="button"><input id="underbar-reveal-show" name="underbar-reveal-show" value="show me" onclick="openOIUnderbar_About();" type="button"></div><div id="underbar-controls-cover"><div id="underbar-controls"><div id="underbar-counter"><img src="dot-inactive.png" id="underbar-dot-0" height="10" width="10"><img src="dot-inactive.png" id="underbar-dot-1" height="10" width="10"><img src="dot-inactive.png" id="underbar-dot-2" height="10" width="10"><img src="dot-inactive.png" id="underbar-dot-3" height="10" width="10"><img src="dot-inactive.png" id="underbar-dot-4" height="10" width="10"><img src="dot-inactive.png" id="underbar-dot-5" height="10" width="10"><img src="dot-inactive.png" id="underbar-dot-6" height="10" width="10"></div><div id="underbar-hide-div"><span style="display: none;" id="hide-link">Hide related links</span><span id="show-link">Show related links</span><input style="display: none;" id="underbar-hide" name="underbar-hide" value="hide me" onclick="closeOIUnderbar();" type="button"><input id="underbar-show" name="underbar-show" value="show me" onclick="openOIUnderbar(1);" type="button"><input style="display: none;" id="underbar-wait" name="underbar-wait" value="loading" type="button"></div></div><div class="underbar-search" id="underbar-search"><form action="http://jac.oxfordjournals.org/content/57/4/619.full" method="post" id="search-form" target="_blank"><label for="underbar-search-oxford-index">Search across all sources</label><input class="underbar-search-oxford-index underbar-search-text-color" id="underbar-search-oxford-index" value="in Oxford Index" onclick="removeDefaultText();" onkeydown="fncKeyDownSearch(event);" type="text">&nbsp;<input id="underbar-search-oxford-index-btn" class="underbar-submit underbar-logo" onclick="return submitSearch();" onkeydown="fncKeyDownSearch(event);" type="submit"></form></div></div></div><div style="display: none;" id="underbar-container"><div id="underbar-container-cover"></div></div><div style="display: none; width: 1261px;" id="underbar_aboutDiv"><div class="underbar-container-about" id="underbar-container-about0"><div style="width: 1213px;" class="underbar-about-columns" id="underbar-about-columns0"><div style="width: 375px;" class="underbar-about-column" id="underbar-about-column_00"><div class="underbar-about-content" id="underbar-about-content_00"><h3>About the Oxford Index</h3><ul><li><div class="alignAbout">A free search and discovery service, the Index helps users begin their research by providing a single, convenient search portal for trusted scholarship from Oxford and our partners.</div></li></ul></div></div><div style="width: 375px;" class="underbar-about-column" id="underbar-about-column_10"><div class="underbar-about-content" id="underbar-about-content_10"><h3>Related Content from Oxford University Press</h3><ul><li><div class="alignAbout">More than just a search tool, the Index provides smart recommendations for related content - from journal articles and scholarly monographs, to reference content, primary sources, and more - based on your research interests.</div></li></ul></div></div><div style="width: 375px;" class="underbar-about-column underbar-about-column-end" id="underbar-about-column_20"><div class="underbar-about-content" id="underbar-about-content_20"><h3>Search across All Books and Journals from Oxford</h3><ul><li><div class="alignAbout">The Oxford Index brings together, for the first time, the best of reference, journals, and scholarly works - one search delivers seamless discovery of all Oxford University Press online content.<br><br>Just enter your search term(s) in the box at the bottom right of your browser, and click the search icon to view your results in a new tab or window.</div></li></ul></div></div></div></div></div><div style="display: none;" id="underbar_noResultsDiv"><div class="underbar-container-noresult" id="underbar-container-about1"><div style="width: 1213px;" class="underbar-about-columns" id="underbar-about-columns1"><div style="width: 375px;" class="underbar-column-noresult" id="underbar-about-column_01"><div class="underbar-about-content" id="underbar-about-content_01"><h3></h3><ul><li><div class="alignAbout"></div></li></ul></div></div><div style="width: 375px;" class="underbar-column-noresult" id="underbar-about-column_11"><div class="underbar-about-content" id="underbar-about-content_11"><h3>NO RELATED LINKS DETECTED</h3><ul><li><div class="alignAbout">We can detect no related content links based on the main page you are currently viewing.<br><br>Related links from the Oxford Index will often be shown here when you are viewing search results or actual content pages on this site.<br><br>Check back here again when viewing other pages to see how the Oxford Index can help you navigate through online content from Oxford University Press and our publishing partners.</div></li></ul></div></div><div style="width: 375px;" class="underbar-column-noresult underbar-about-column-end" id="underbar-about-column_21"><div class="underbar-about-content" id="underbar-about-content_21"><h3>YOU CAN ALWAYS SEARCH THE INDEX DIRECTLY</h3><ul><li><div class="alignAbout">Use the search box on the right of the Oxford Index bar to search across all book and journal content available from Oxford University Press and our publishing partners.<br><br>Results will open in a new browser window or tab, so you can keep your place on this site while you explore related material.</div></li></ul></div></div></div></div></div></div></div><img style="display: none;" src="listener2_002.dat"><img style="display: none;" src="listener2_003.dat"><img style="display: none;" src="listener2_004.dat"></body>
</html>
